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AIA

POST-GRANT REVIEW & EUROPEAN OPPOSITIONS:
WILL THEY WORK IN TANDEM,
OR RATHER PASS LIKE SHIPS IN THE NIGHT?

Filip De Corte,* Anthony C. Tridico," Tom Irving,**
Stacy D. Lewis*" & Christina N. Gervasi""'
Perhaps the new post-grant review proceeding in the United States
was conceived in the likeness of a European opposition, but as it
moved from conception to reality, a unique American
administrative proceeding was created that does not bear much
resemblance to its European inspiration. This Article describes
features of both post-grant review and European oppositions and
argues that the differences between them mean they will not work
in tandem, but rather will generally pass like ships in the night.
Notably, the ships will not necessarilycrash either, and they could
even be part of the same fleet.
1. INTRODUCTION

The Leahy-Smith America Invents Act of 2011 ("AIA")'
effects the first major overhaul of the U.S. patent system since the
Ph.D.; Chief Intellectual Property Counsel Europe for Cargill, an
international producer and marketer of food, agricultural, financial, and
industrial products and services.
Ph.D.; Managing Partner at Finnegan, Henderson, Farabow, Garrett &
Dunner, L.L.P. (Brussels, Belgium).
Partner at Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
(Washington, DC).
Law Clerk at Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
(Washington, DC).
U.S. Patent Agent and J.D. Candidate at the University of Dayton School
of Law (2013).
1Pub. L. No. 112-29, 125 Stat. 284 (2011) (codified as amended in scattered
sections of 35 U.S.C.). Portions of the Leahy-Smith America Invents Act were
not codified in 35 U.S.C., so some of the changes it makes to U.S. patent law
will be found only in the text of the AIA.
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venerable Patent Act of 1952. 2 There were significant but
unsuccessful prior attempts at reform in the ten years leading up to
the passage of the new law.3 The motivation for reform came from
widespread frustration with the United States Patent and
Trademark Office ("USPTO") over an ever-growing backlog of
patent applications awaiting examination' and suggestions that the
USPTO was allowing too many "weak" patents. There also was
(and is) frustration with patent litigation over "runaway"
discovery, increasing time and costs, and the rise of non-practicing
entities ("NPEs") winning very large damage awards. 6 However,
Pub. L. No. 82-593, 66 Stat. 792 (1952) (codified as amended at 35 U.S.C.
§§ 1-376 (2006)).
E.g., Patent Reform Act of 2009, S. 515, 11Ith Cong. (2009); Patent Reform
Act of 2007 S. 1145, 110th Cong. (2007); Patent Reform Act of 2005, H.R.
2795, 109th Cong. (2005); see also FED. TRADE COMM'N, To PROMOTE
2

INNOVATION: THE PROPER BALANCE OF COMPETITION AND PATENT LAW AND
POLICY (2003).
4 The AIA amended 35 U.S.C. § 299 in specific response to the rise of
lawsuits brought by non-practicing entities. For any civil action commenced on
or after September 16, 2011, joinder of defendants is only allowed if the claim
for relief arises from "the same transaction, occurrence, or series of
transactions" and "questions of fact common to all defendants . . . will arise in
the action." 35 U.S.C. § 299(a) (Supp. V 2011). The statute specifies that
simply having the same patent as the basis for the infringement allegation is not
enough for joinder. See 35 U.S.C. § 299(b) (2006). The case of Optimum
Power Solutions LLC v. Apple Inc. was one of the first to see a judge apply the
new AIA joinder provision. No. Cl1-1509SI, 2011 WL 4387905 (N.D. Cal.
Sept. 20, 2011). The plaintiff proposed ten defendants. Id. at *1. The district
court dismissed the case against all but one of the defendants. Id. at *3.
5 "Weak" patents are those that are easily designed around. See ZHEN LEI &
BRIAN D. WRIGHT, WHY WEAK PATENTS? 1-2 (2009), available at
http://ageconsearch.umn.edu/bitstream/49279/2/LeiWrightAAEA_2009.pdf.
The resources spent on innovation and then obtaining the patent become
worthless because the patent obtained is easily circumvented. Id. at 1 ("Weak
patents incur social costs without commensurate social benefits.").
6 NPEs are companies that do not make or practice invention themselves, but
rather apply for or acquire patents solely to obtain a licensing revenue stream or
See
judgments.
litigation
adverse
through
money
obtain
PRICEWATERHOUSECOOPERS LLP, 2011 PATENT LITIGATION STUDY 34 (2011).

Sometimes they are derogatively referred to as "patent trolls." What is a Patent
Troll?, PATENTLY-O (May 12, 2006, 6:30 AM), http://www.patentlyo.com/paten
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those earlier attempts at U.S. patent reform never gathered
sufficient political will and were unsuccessful in resolving
differences between stakeholders in the patent community with
very different priorities.' Examples of such stakeholders with
competing visions of change were individual American inventors
and large multi-national corporations facing global competition,
software and high-tech industries making products with a very
short shelf-life, and innovative pharmaceutical companies facing
years of regulatory approval between the date of invention and
getting a product to market after Food and Drug Administration
approval. Finally, the 112 th Congress managed to broker what can
fairly be labeled a compromise agreement, and the new law was
signed by President Obama on September 16, 201 1.8 Those who
support the new law hope that it will make prosecuting patents
more efficient, reduce patent litigation in the U.S. federal district
courts by providing more extensive post-grant cancellation
proceedings in the USPTO, foster innovation, and ensure that the
United States is globally competitive in technological areas.
In an effort to achieve those goals, the AIA altered several
aspects of U.S. patent law.9 This Article will focus specifically on
one such change: post-grant review. Post-grant review ("PGR") is
a new administrative proceeding in the USPTO, whereby a third
party may provide information in the hope that the USPTO will
reconsider and cancel the original patent claim."o There are two
other possible PGR outcomes: The claims are maintained by the
USPTO without change (i.e., they withstand post-grant review) or
at least one claim may be amended at the USPTO to preserve the
patentability of that one claim." If at least one claim is amended,
t/2006/05/what is a-paten.html; see generally Peter J. Stern & Timothy G.
Doyle, Trends andDevelopments RegardingNonpracticingEntities in the U.S.,
61 CHIZAI KANRI 445 (2011) (exploring the relationship between traditional
companies and NPEs).
7See sources cited supra note 3.
8 Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011)
(codified as amended in scattered sections of 35 U.S.C.).
9Id.
1OId. at sec. 6.
" See id.
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the claim as amended at the USPTO may no longer cover a third
party's allegedly infringing product, which is as good for the third
party as if the claim had been cancelled. 2
Before the AIA, the cancellation options before the USPTO
available to a third party were third party prior art submissions," ex
parte reexamination, 14 and inter partes reexamination." Those
options were criticized by the patent community as inadequate in
the case of third party prior art submissions; too narrow in scope,
and too lengthy in pendency in the case of ex parte reexamination;
and too risky in the case of inter partes reexamination in view of
its estoppel provisions." In addition, there were (and are) many
concerns about using the judicial system to resolve patent disputes
in the United States, including, but not limited to cost, nearly
unlimited discovery, lay juries, and lengthy pendency.
PGRs are intended to be quasi-judicial administrative
proceedings that will help relieve some of the burden of patent
litigation from the U.S. federal courts. At first blush, it may seem
strange to add to the USPTO's responsibilities when it was already
struggling to meet its workload, but the promises of increased staff
and improved efficiency may be sufficient to address this issue."
In creating a proceeding to meet the objective of relieving the
U.S. federal courts and to answer the shortfalls in the old, pre-AIA
system, as exemplified above, American legislators initially looked
to the example of opposition proceedings in the European Patent

12 See id.

See 35 U.S.C. §§ 301-302 (2006).
See id. §§ 302-307.
" See id.§§ 311-319.
16 COMM'R FOR PATENTS, U.S. PATENT
14

AND TRADEMARK OFFICE, EX PARTE

REEXAMINATION FILING DATA (2012), available at http://www.uspto.gov/patent

s/stats/EPquarterlyreport June_30_2012.pdf. Average pendency for an ex
parte reexamination, for example, for the time period July 1981 to June 2012
was 25.4 months. Id.
'7 Interview with David Kappos, Director, USPTO, at American Intellectual
Property Law Association Annual Meeting (Sept. 30, 2011) (indicating that the
USPTO is seeking to fill as many as 2,000 new Patent Examiner positions and
150 new Administrative Patent Judge positions).
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Office ("EPO") as a model for a PGR." The EPO opposition is
ingrained in multinational patent practice, and operates as a
revocation proceeding where third parties can challenge the
validity of European patents in the EPO. Although conceived in
the likeness of an EPO opposition, by the time the AIA passed,
PGR had morphed into a uniquely American administrative
proceeding that does not bear much resemblance to its European
inspiration. In practice, the AIA will operate much differently than
an EPO opposition, although both the EPO opposition and PGR
are designed as revocation or cancellation proceedings that should
be less expensive than litigation in the courts.
This Article describes and compares features of both PGRs and
European oppositions, and argues that the differences between
them mean they will not necessarily work in tandem, but rather
will generally pass like ships in the night. If PGRs and oppositions
worked in tandem, there could be procedural possibilities such as
stays in favor of the first-filed proceeding, formal discovery and
evidence sharing, and res judicata. However, the systems will
remain separate because neither the USPTO nor the EPO will stay
a proceeding pending resolution in the other tribunal, there will not
be any provision for the USPTO and the EPO to share discovery or
evidence in revocation or cancellation proceedings, and there will
be no res judicata between the EPO and the USPTO. Thus,
although oppositions and PGRs will be completely separate
substantively and procedurally, the timing could work out so that
both processes could run simultaneously.
Notably, the ships will not necessarily crash either. That is,
oppositions and PGRs are not inherently conflicting proceedings.
They are simply alternative revocation and cancellation
8 The European Patent Office provided an overview of the opposition
procedure in 2001. Opposition Procedure in the EPO, 2001 O.J.E.P.O. 148
(2001), availableat http://archive.epo.org/epo/pubs/oj001/03 01/03 1481.pdf.
19 Simultaneous proceedings will likely be rare, since both PGRs and
oppositions have a nine-month post-issuance deadline in which to bring an
action. See discussion infra Parts II.C, 1II.D. For a PGR and opposition to be
running simultaneously, the U.S. and European patents would have had to issue
at (or nearly at) the same time.
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proceedings for different times in the life of an invention patented
both in the United States and Europe; PGRs will be an alternative
in the first nine months after a U.S. patent issues, and oppositions
will be an alternative in the first nine months after a European
patent issues. The two alternatives include different laws, different
procedures, and different patents. Perhaps, if the PGR occurs first,
the discovery allowed in the United States will reveal prior art that
could then be used in an opposition on the related European patent
(if the opposition filing deadline has not passed). This will be
serendipitous rather than guaranteed. The qualification that the
ships will not "necessarily" crash is included because statements
made in foreign proceedings that contradict positions taken in U.S.
proceedings have been used against the patentee in U.S.
proceedings and may be the type of "inconsistent statement" that
will have to be provided by the patentee to the petitioner in the
PGR.20
Part II discusses the details of EPO oppositions. Part III
describes PGRs, providing comparisons to oppositions. The
Article concludes with Part IV, discussing strategic considerations
accompanying the use of European oppositions and PGRs.
II. EPO OPPOSITIONS

The European Patent Convention 21 of October 5, 1973,
introduced a post-patent grant opposition procedure.22 The EPO
See, e.g., Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed.
Cir. 2011) (en banc); Rules of Practice for Trials Before the Patent Trial and
Appeal Board and Judicial Review of Patent Trial and Appeal Board Decisions,
77 Fed. Reg. 48,612, 48,673 (Aug. 14, 2012) (to be codified at 37 C.F.R.
§ 42.5 1(b)(1)(iii)).
21 Convention on the Grant of European Patents, Oct. 5, 1973, 1065 U.N.T.S.
199 [hereinafter 1973 European Patent Convention]. The European Patent
Convention (EPC) is the treaty that established a unified granting procedure
amongst the Member States of the EPC. Id. Original Member States were
Belgium (BE), Switzerland (CH), Germany (DE), France (FR), Great-Britain
(GB), Luxemburg (LU), The Netherlands (NL) that all acceded to the EPC on
October 7, 1977 and Italy (IT) that joined on December 1, 1978. Id. This treaty
created the European Patent Organization. Id.
22 id.
20
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seems to adhere to the philosophy that the opposition is an
excellent tool to improve the quality of the patents it grants.
Despite the relatively explicit bias towards applicants, the EPO
does recognize its obligation to the public, who need to be
protected against "bad" patents.23 Oppositions allow third parties
(other than the applicant and the EPO) to bring forward facts and
arguments that are prejudicial to the patentability of the invention
that is claimed in the opposed patent. These facts and arguments
will often be those other than printed publications, such as oral
disclosures at a conference or public prior use by a third party,
making them difficult for examiners to access.24
Oppositions are peculiar because they constitute a centralized
revocation procedure affecting the bundle of national rights that
originate from the granted European patent, thereby bringing the
European patent back under the reach of the EPO after its prime
examination authority ended at the moment of grant. 2 The
European Patent Convention opted for a post-grant opposition
instead of the pre-grant opposition, which existed in a number of
member states as a compromise position between the position of
some member states that did not have any opposition procedure at

"Bad" patents are those that do not warrant the temporary exclusionary
power that a patent offers to its owner in exchange for the technological
information contained in the patent. See Matthew Sag & Kurt Rohde, Patent
Reform and DifferentiallImpact, 8 MINN. J.L. SC. & TECH. 1, 12-14 (2006). For
example, claims that are actually anticipated in the prior art are not "novel" and
therefore the patents do not promote progress and innovation in science and the
public should not be prevented from practicing the claimed technology for the
limited time of protection a patent provides. See Mark A. Lemley, Rational
Ignorance at the PatentOffice, 95 Nw. U. L. REv. 1495, 1522-23 (2001).
24 For an overview of the search documentation available to European Patent
Examiners, see EUROPEAN PATENT OFFICE, GUIDELINES FOR EXAMINATION IN
23

THE EUROPEAN PATENT OFFICE, pt. B, ch. IX

§§ 1-5 (2012), available at

http://documents.epo.org/projects/babylon/eponet.nsf/0/6c9c0ec38c2d48dfcl25
7a21004930f4/$FILE/guidelines for examination_2012_en.pdf.
25 Convention on the Grant of European Patents, art. 99-105, Oct. 5, 1973,
1065 U.N.T.S. 199, as revised Nov. 29, 2000 [hereinafter European Patent
Convention].
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all and other member states that had one form of opposition
procedure (pre-grant or post-grant).26
Even though the opposition as defined in the European Patent
Convention is a post-grant revocation procedure and manifestly is
an inter partes procedure, it clearly has the character of an
"enhanced" patent examination rather than a litigation. 27 This
examination character is epitomized by the fact that the Examiner
conducting the examination is a member of the Opposition
Division.28
A. Parties
Any person may give notice to the EPO of an opposition to a
granted patent. 29 However, the Enlarged Board of Appeal decided
in 1997 that the patent owner is excluded from filing an opposition
against his own patent because of the fundamental inter partes
nature of the opposition.30 Until that decision, patent owners did
Opposition Procedure in the EPO, 2001 O.J.E.P.O. 148 (2001), available at
http://archive.epo.org/epo/pubs/oj001/03_01/03-1481.pdf.
27 See European Patent Convention, supra note 25,
at art. 19.
28 Article 19 of the European Patent Convention describes the composition
of
the Opposition Division, and it stipulates that this Opposition Division will
consist of three examiners, "at least two of whom shall not have taken part in the
proceedings for grant of the patent to which the opposition relates." Id This
implies (and that is actually the ordinary course of business) that one member is
indeed an examiner who took part in the examination up to grant.
29 European Patent Convention, supra note 25, at art. 99.
30 Case G 1/84, Opposition by Proprietor/MOBIL OIL,
1985 O.J.E.P.O. 10,
299-305 (Enlarged Bd. Appeal, July 24, 1985), availableat http://archive.epo.
org/epo/pubs/oj 1985/p299 332.pdf (finding initially that the Enlarged Board
had found that "self opposition" was permissible, as the proprietor of a patent
could be regarded as "a person"). But see Case G 3/97, Opposition on Behalf of
a Third Party/INDUPACK, 1999 O.J.E.P.O. 245, 245-70, (Enlarged Bd.
Appeal, Jan. 21, 1999), availableat http://archive.epo.org/epo/pubs/oj99/5_99/5
2459.pdf; Case G 4/97, Opposition on Behalf of a Third Party/GENETECH,
1999 O.J.E.P.O. 270, 270-72 (Enlarged Bd. Appeal, Jan. 21, 1999), availableat
http://archive.epo.org/epo/pubs/oj99/5_99/5_2709.pdf.; Case G 9/93, Opposition
by Patent Proprietor/PEUGEOT AND CITROEN, 1994 O.J.E.P.O. 12, 891-97
(Enlarged Bd. Appeal, July 6, 1994), available at http://archive.epo.org/epo/pub
s/oj1994/p875_981.pdf. The G 1/84 position was later overruled in Enlarged
Board of Appeal decision G 9/93, in which "any person" was construed as
26
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file self-oppositions as a way to amend, correct, or limit the claims
after grant."
An opposition may also be filed by a "straw man," a person
who files an opposition in his own name while acting for
somebody else (usually someone who wants to stay anonymous).32
The EPO accepts these oppositions as long as the use of a straw
man does not circumvent the law (for instance, the patent owner is
not allowed to use a straw man to oppose his own patent)." The
European Patent Convention also allows an opposition by an
alleged infringer in the case where the patent holder of the opposed
patent has initiated court proceedings against said alleged
infringer.34
There can obviously be more than one opponent, but there is no
requirement that they act jointly. 5 Opponent status is not a freely
meaning anyone except the patent proprietor. See Case G 9/93, Opposition by
Patent Proprietor/PEUGEOT AND CITROEN, 1984 O.J.E.P.O. at 891-97. This
was reinforced by the Enlarged Board of Appeal decisions in G 3/97 and G 4/97,
which held that it was permissible to act as an opponent on behalf of a third
party, provided that the third party in question was not the patent proprietor.
Case G 3/97, Opposition on Behalf of a Third Party/INDUPACK, 1999
O.J.E.P.O. at 245-70; Case G 4/97, Opposition on Behalf of a Third
Party/GENETECH, 1999 O.J.E.P.O. at 270-72.
31 Case G 1/84, Opposition by Proprietor/MOBIL OIL, 1985 O.J.E.P.O. at
299-305 (attempting correction of a patent similar to proceedings available to
patent owners in the United States under 35 U.S.C. § 251 (2006) (reissue) and
35 U.S.C. § 302 (2006) (exparte reexamination)).
32 A "straw man" is often used in the United States to request ex parte
reexamination when anonymity is desired. See 35 U.S.C. § 322(a)(3) (Supp. V
2011). In contrast, under AIA, a petition for PGR must be filed by a real party
in interest. See discussion infra Part III.B.
33 See Case G 3/97, Opposition by Patent Proprietor/INDUPACK, 1984
O.J.E.P.O. at 891-97.
34 European Patent Convention, supra note 25, at art. 105. As has been
demonstrated, AIA provides an analogous approach, but there are time limits as
discussed above. See 35 U.S.C. § 315 (Supp. V 2011).
35 Case G 3/99, Admissibility of Joint Opposition or Joint Appeal/HOWARD
FLOREY, 2002 O.J.E.P.O. 347, 347-63 (Enlarged Bd. Appeal, Feb. 18, 2002),
In
available at http://archive.epo.org/epo/pubs/oj002/07_02/07_3472.pdf.
Enlarged Board of Appeal decision G 3/99, the Board held that multiple parties
could file a single joint opposition. Id. Only a single opposition fee need be
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transferable business asset, 6 though it can be transferred together
with other business assets when a complete business is sold."
B. Grounds
There are only three main" grounds on which an opposition
can be based. These are set forth in Article 100 of the European
Patent Convention as (1) the granted patent does not meet the
requirements for patentability under Articles 52-57 EPC; (2) the
granted patent does not disclose the claimed invention sufficiently
clearly and completely for it to be carried out by a person skilled in
the art;4 o or (3) the subject matter of the patent has been extended
beyond the scope of the application as originally filed or, in the
case of divisional or replacement applications, beyond the scope of
the earlier applications on which they are based.4
paid, but all actions must be undertaken by a common representative. Id. If no
common representative is expressly appointed, the first-named opponent is
deemed to take this role. Id.
36 Case G 2/04, Transfer of Opposition/HOFFMANN-LA ROCHE, 2005
O.J.E.P.O. 549, 549-76 (Enlarged Bd. Appeal, May 25, 2005), available at
http://archive.epo.org/epo/pubs/oj005/1 105/115495.pdf (holding that the
status as opponent cannot be freely transferred).
3 Case G 4/88, Transfer of Opposition/MAN, 1989 O.J.E.P.O. 480, 480-82
(Enlarged Bd. Appeal, Apr. 24, 1989), available at http://archive.epo.org/
epo/pubs/oj1989/p479_530.pdf. In Enlarged Board of Appeal decision G 4/88,
the Board decided that the opposition could be transferred to the opponent's
universal successor in law. Id. AIA raises an analogous issue in Prior
Commercial Use. See 35 U.S.C. § 273(e)(1)(B) (Supp. V 2011); Leahy-Smith
America Invents Act, Pub. L. No. 112-29, 125 Stat. 298 (2011) (codified as
amended in scattered sections of 35 U.S.C.).
38 Case G 1/95, Fresh Grounds for Opposition/DE LA RUE, 1996 O.J.E.P.O.
615, 615-25 (Enlarged Bd. Appeal, July 19, 1996), availableat http://archive.ep
o.org/epo/pubs/oj1996/p615 648.pdf. The word "main" is used because by
decision of the Enlarged Board of Appeal G 1/95 that indicated ground 100(a) is
actually a collection of separate grounds (novelty, inventive step, etc.). Id
39 European Patent Convention, supra note 25, at art. 52-57
(defining
patentable subject matter, exceptions to patentability, novelty requirements, nonprejudicial disclosures, the inventive step requirement, and industrial
ap licability requirements).
Id. at art. 83.
41 Id. at art. 123.
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As mentioned above, the list of grounds set out in Article 100
EPC42 is exhaustive. To the frustration of many opponents, clarity
of the claims is not ground for opposition,4 3 although, as has been
observed by European practitioners, that is often exactly the issue
that the opponent would like to attack.
Even though clarity is not a ground for opposition, the clarity
requirement can play its role once amendments are made to the
granted claims.44 Objections based on lack of clarity and support
can be raised against amendments filed during the opposition
process. In contrast, lack of unity is not relevant at any stage
during opposition proceedings, even if a patent is amended.45
An opposition is, in principle, limited to the grounds raised
when a notice of opposition is filed.46 The EPO Opposition
Division may raise a ground for opposition of its own motion even
if that ground was not covered in the opposition request or
consider a ground not covered when raised by an opponent later
only under strict conditions.47 In particular, raising a new ground
can only take place where, prima facie, there are clear reasons to
believe that such grounds are relevant and would in whole or in
part prejudice the maintenance of the European patent.48 During
the appeal, further grounds can only be introduced with the consent
of the patent owner.49

42

Id. at art. 138.

43 Id.

Id.
Case G 1/91, Unity/SIEMENS, 1992 O.J.E.P.O. 253, 253-59 (Enlarged Bd.
Appeal, Dec. 9, 1991), available at http://archive.epo.org/epo/pubs/ojl992/
p253_336.pdf.
46 Case G 9/91, Power to Examine/ROHM AND HAAS, 1993 O.J.E.P.O.
408,
408-20 (Enlarged Bd. Appeal, Mar. 31, 1993), available at http://archi
ve.epo.org/epo/pubs/ojl993/p403 475.pdf.
47 id
48
See id. at 418.
49 See Case G 1/95, Fresh Grounds for Opposition/DE LA RUE, 1996
O.J.E.P.O. 615, 615-25 (Enlarged Bd. Appeal, July 19, 1996), available at
http://archive.epo.org/epo/pubs/oj1996/p615_648.pdf; Case G 7/95, Fresh
Grounds for Opposition/ETHICON, 1996 O.J.E.P.O. 626, 626-27 (Enlarged Bd.
4

45
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Where only some claims are opposed, the Opposition Division
is again in principle limited to considering the validity only of the
opposed claims." As a consequence, it is important for opponents
to ensure that they enter all arguments to support an attack under
each of the grounds. When an opponent fails to do so, he runs the
risk that when other elements relating to a ground that was not
raised in his notice of opposition arise during the opposition, he is
no longer able to raise these elements in the proceedings. "
Likewise, it is important to have an attack on every claim (not just
the independent claims) to ensure that, according to a term of art
among EPO participants, all claims are "in the opposition." By
way of comparison, in a PGR, the requester is estopped from
requesting or maintaining a proceeding based on an issue that he
"raised or reasonably could have raised" in another USPTO
proceeding and in any subsequent civil litigation.52
C. Procedureand Timing
An opposition needs to be filed within nine months of the
publication of the "mention of the grant"" in the European Patent
Bulletin." The U.S. period for PGR is the same."
It is important to note that in both systems, the nine-month
opposition period cannot be extended." However, the European
Patent Convention allows a means for an alleged infringer to
Appeal, July 19, 1996), available at http://archive.epo.org/epo/pubs/ojl996/
p615 648.pdf.
5o See Case G 9/91, Power to Examine/ROHM AND
HAAS, 1993 O.J.E.P.O.
at 408-20; Case G 10/91, Examination of Oppositions/Appeals 1993 O.J.E.P.O.
420, 420-21 (Enlarged Bd. Appeal, Mar. 31, 1993), available at http://archive.
epo.org/epo/pubs/oj l993/p403_475.pdf.
51See discussion infra Part II.D.
52 35 U.S.C. § 325(e) (Supp.
V 2011).
5 European Patent Convention, supra note 25, at art. 99. The "mention of the
grant" is a particular date that the patent is granted in the European Patent
Bulletin. See id
54 The European Patent Bulletin, EUROPEAN PATENT OFFICE, http://www.epo
.org/searching/free/bulletin.html (last visited Oct. 7, 2012).
5 35 U.S.C. § 321(c) (Supp. V 2011).
56 See id. § 321 (Supp. V 2011); European Patent Convention,
supra note 25.
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intervene in opposition proceedings after the nine-month
opposition period has expired." To do so, the alleged infringer
must supply the EPO with evidence that the patent owner has
initiated court proceedings against the alleged infringer." The
intervener59 must also file a notice of intervention and pay an
opposition fee." All these steps must be taken within three months
after the initiation of the court proceedings." In the United States,
by way of comparison, after nine months post-issuance a third
party may only challenge a patent via alternative routes in the
USPTO, e.g., inter partes review ("IPR") or ex parte
reexamination.62
An opposition may be filed even though the European patent
was surrendered (explicitly given up in a specific country) or
lapsed.63 In other words, even if the patent was granted, and then
surrendered, an opposition may be filed prior to the expiration of
the nine months post-issuance.
One or more opponents initiate opposition by filing a notice of
opposition.' The notice of opposition must include enough details
to identify the opponent, the number of the European patent being
opposed, the extent to which the patent is being opposed, the
grounds on which the opposition is based, and an indication of the
facts and evidence the opposition relies upon.65 Failure to file the
opposition on time, to provide grounds, or to identify the patent
being opposed renders an opposition inadmissible unless the

58

European Patent Convention, supra note 25, at art. 105.
id

59Id.

Id. at rule 89(2).
rule 89(1).
62 See 35 U.S.C. § 302 (Supp. V 2011) (ex parte reexamination); 35 U.S.C.
§ 311(c) (Supp. V 2011) (interpartes review).
63 EPO GUIDELINES, supra note 24, pt. D, ch. VIl,
§ 5.1. The effect of the
decision at the end of the opposition is ab initio. Id. Consequently, even though
the patent was surrendered or lapsed, one can retroactively establish that the
patent was not validly granted.
6 European Patent Convention, supra note 25, at art. 99(1).
6 Id at rule 76(2).
60

61 Id. at
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omissions are corrected before the end of the nine-month
opposition period.66
When a notice of opposition is received, the Opposition
Division first checks that it was filed within the nine-month
opposition period, that it includes a statement of grounds and
identifies the patent being opposed, and that the opposition fee has
been paid. 67 If the notice fails to comply with any of these
requirements, the opposition is rejected.8
The opposition is also checked for compliance with the other
formalities69 and any omissions or deficiencies must be remedied
before a deadline set by the EPO. When the opponent does not
remedy these deficiencies or omissions in due time, the opposition
will be deemed inadmissible, and the opponent cannot rely on
further processing."o
If the opposition is admissible, the Opposition Division will
invite the patent owner to comment on the opposition.7 " The
Opposition Division will set a time limit for responding, normally
four months, but an extension can be obtained upon request.72 The
Opposition Division has a certain degree of freedom to allow for a
further round of exchange of arguments."
EPO GUIDELINES, supra note 24, pt. D, ch. IV, § 1.2.1.
European Patent Convention, supra note 25, at art. 99(1).
68 Id. at art. 99, rule
77(1).
69
Id. at rule 76.
70 Id.; see European Patent Convention, supra note 25, at
art. 121 (noting that
further processing is available to the applicant during prosecution upon failure to
observe a time limit, however neither the opponent nor the patentee can make
use of it during proceedings).
n' EPO GUIDELINES, supra note 24, pt. D, ch. IV, § 5.2.
72
Id. at pt. D, ch. IV, § 3.1.
7 European Patent Convention, supra note 25, at art. 101(1) ("During this
examination, the Opposition Division shall invite the parties as often as
necessary to file observations on communications from another party or issued
by itself."); see also European Patent Convention, supra note 25, at rule 81(2)
("Communications under Article 101 paragraph 1, second sentence, and all
replies thereto shall be sent to all parties. If the Opposition Division considers
this expedient, it shall invite the parties to reply within a period to be
specified."); EPO GUIDELINES, supra note 24, pt. D, ch. VI.
66

67
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When the patent owner or the opponents have requested oral
proceedings, which they normally will do, the Opposition Division
will invite the parties for those proceedings. 7 Often the
Opposition Division will issue a preliminary decision along with
an invitation to comment or focus argumentation during the oral
proceedings on certain questions.
Oral proceedings occur in the vast majority of oppositions.76
The Opposition Division strives to use oral proceedings as a means
to come to a final decision in an efficient way. However, it is
possible that the Opposition Division will decide to continue the
proceedings in writing.
During the opposition, the owner is given the opportunity to
amend the opposed patent, but the patent owner is not allowed to
benefit from the opposition to improve parts of the patent that are
unrelated to the opposition." The amendments filed by the patent
owner must be clear, concise, and supported by the content of the
description.
An opponent may object to amendments on the basis that they
add mattero and that they would extend the scope of protection
beyond that originally granted."' In PGR, there is authorization for
the patent owner to make one amendment to the claims and,
74
7
76

EPO GUIDELINES, supranote 24, pt. E, ch. II, § 1.1.
Id. at § 5.5.
ALFRED

SPIGARELLI,

EUROPEAN

PATENT

OFFICE,

THE OPPOSITION

PROCEDURE AT THE EPO 10 (2012), available at http://www.ipo.org/AM/Templ

ate.cfm?Section=Calendar&Template=/CM/ContentDisplay.cfm&ContentlD=3
3222 (noting that in eighty-five percent of the cases, the Opposition Division's
first action is a summons to oral proceedings, and in fifty percent of the
remaining fifteen percent of the cases, a summons to oral proceedings is issued
in the end).
n European Patent Convention, supra note 25, at art. 99(1).
78 See
id. at art. 123(3); Case T 0195/09, Scale Inhibiting
Polymers/UNILEVER, at *10-11 (Bd. App. of the European Patent Office,
October 8, 2010), available at http://www.epo.org/law-practice/case-law-appeal
s/pdf/t090195eul.pdf.
7 European Patent Convention, supra note 25, at art. 101(3).
'0 Id. at art. 123(2).
8 Id. at art. 123 (3).
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similar to European oppositions, an amendment may not broaden a
claim. 82 The patent owner may move to request another
opportunity to amend the claims."
If the Opposition Division decides that none of the grounds
raised by the opponent prejudices, i.e., provides a basis for
revocation of the opposed patent, it will reject the opposition.8 4 If
at least one of the grounds prejudices the patent, the patent is
revoked." Alternatively, the Opposition Division may find that
amendments made by the owner overcome the objections raised
and may maintain the patent in amended form.86
Both in the case of revocation and in the case of maintenance
of the patent, the final decision in the EPO can be clear-cut: Either
there is no patent or the patent stands as it was granted. However,
when the Opposition Division decides that. the patent can be
"maintained in amended form," the claims and often also the
description need to be amended."
As a result, the Opposition Division needs to obtain the
approval of the amended text by the patent owner," while the
opponent needs sufficient opportunity to comment upon the
amended text and description. If the Opposition Division is of the
opinion that the patent can be maintained on the basis of the text
approved by the patent owner, it issues an interlocutory decision.89
See Changes to Implement Inter Partes Review Proceedings, Post-Grant
Review Proceedings, and Transitional Program for Covered Business Method
Patents, 77 Fed. Reg. 48,680, 49,730 (Aug. 14, 2012) (to be codified at 37
C.F.R. § 42.221.
82

83 Id
84

European Patent Convention, supra note 25, at art. 101(2).

85 Id.

86 Id.

at art. 101(3).

88

Id. at art. 113(2).

89

EPO GUIDELINES, supra note 24, pt. D, ch. VI,

§ 7.2.2. An interlocutory

decision is issued because a final decision automatically triggers the deadline for
filing translations of the claims. Id at pt. D, ch. VI, § 7.2.1. The European
Patent Office, however, wants to allow the patent proprietor to avoid starting
preparations for translations if doubt remains about the final text of the claims or
description. Id.
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Once this interlocutory decision becomes final, the owner of the
patent must pay the printing fee for a new patent specification and
file a translation of any amended claims within three months."
The average duration of the opposition procedure at the EPO is
thirty-four months. 9' When accelerated prosecution is requested,
the opposition can be concluded in twelve months.92 The first
requests for transitional PGR proceedings for covered business
method ("CBM") patents were just filed on September 16, 2012,
under the program for CBM patents.9 3 These CBM transitional
PGRs will be analogous to PGRs that will apply to any patent
having at least one claim with an effective filing date after March
15, 2013.94 While the statute requires a final decision on the CBM
transitional PGRs (and regular PGRs) by one year after the
proceeding is instituted,9 5 it remains to be seen what the average
duration for PGRs will actually be.
The Opposition Division consists of three "technically
qualified" members." In most cases, one of the members will be
90

Id. at pt. D, ch. VI, § 7.2.3.

91 SPIGARELLI, supra note 76, at 10.
92 LAURA RAMSAY, DEINS, HOW TO GET A PATENT QUICKER-EUROPE

(2010), availableat http://www.dehns.com/cms/document/how toget-a-patent
quicker europe.pdf.
9 Leahy-Smith America Invents Act, Pub. L. No. 112-29, sec. 18, 125 Stat.
284, 329-31 (2011) (codified as amended in scattered sections of 35 U.S.C.).
Twelve CBM transitional PGRs had been filed as of October 15, 2012. See
Search for a Case, USPTO.GOv, https://ptabtrials.uspto.gov/prweb/PRServlet/
oO9O9iMscyJcfy6LnBDXO9xEtRpDxf L3At36r8Aw8k%5B*/!STANDARD?
(last visited Nov. 16, 2012).
94 Leahy-Smith America Invents Act sec. 6(f)(2)(A).
9 Id. sec. 18(a)(1). For regular PGRs, decisions must be rendered within one
year from the date on which the PGR is instituted:
[Flinal determination in any post-grant review [shall] be issued not later
than 1 year after the date on which the Director notices the institution of a
proceeding under this chapter, except that the Director may, for good cause
shown, extend the 1-year period by not more than 6 months, and may adjust
the time periods in this paragraph in the case of joinder under section
325(c).
35 U.S.C. § 326(a)(l 1) (Supp. V 2011).
96 European Patent Convention, supra note
25, at art. 19(2).
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the primary examiner who dealt with the patent application before
the grant. The two other members will not have taken part in the
prosecution of the patent; the chairman of the Opposition Division
will be one of these two.97
Although one of the members is entrusted with the examination
of the opposition, the oral proceedings have to take place before
the complete Opposition Division." If the Opposition Division is
of the opinion that the case at hand requires it, a "legally qualified"
examiner might be added to the Division.99 The presence in the
Opposition Division of an examiner who was involved in the
proceedings for grant of the patent obviously ensures that at least
one of its members is very familiar with the facts and documents of
the case. It implicitly shows that opposition proceedings are a
post-grant continuation of examination rather than a judicial
review of the case.
By comparison, in creating PGRs in the United States,
Congress deliberately chose to use the Patent Trial and Appeal
Board ("PTAB") as the tribunal of first instance."'o PTAB will be
staffed by Administrative Patent Judges, not examiners."o' Under
ex parte reexamination in the United States, the reexamination
goes to the Central Reexamination Unit ("CRU") in the first
instance.10 2 The CRU is staffed by the examining corps, but it has
been observed that generally the CRU examiner is not the
examiner who examined the original patent being reexamined.'

97 id.

98

d.

99 Id. Because the examination up to grant never involves a legally qualified
member, this legally qualified member may not be involved in the examination
procedure up to grant.
0 See 35 U.S.C. § 326(c) (Supp. V 2011).
101 See 35 U.S.C. § 6(a) (2006); Leahy-Smith America Invents Act, Pub. L.
No. 112-29, sec. 7, 125 Stat. 284, 313-15 (2011) (codified as amended in
scattered sections of 35 U.S.C.).
102

U.S. PATENT & TRADEMARK OFFICE, MANUAL OF PATENT ExAMINING

PROCEDURE § 2236 (2012), available at http://www.uspto.gov/web/offices/pac/
mpep/s2236.html.
i03

id
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The opposition fee that needs to be paid before the expiration
of the time limit for opposition amounts to C745."> Each separate
opponent must pay the opposition fee. For "joint" opponents, only
one fee is required."o' In the United States, the fee to file a petition
for PGR is presently set at $35,800, and that is only if the petition
requests review of between one and twenty claims.'06 For every
additional claim beyond twenty, there is an additional $800 in
fees. 107
Consequently, from the point of view of administrative fees,
the barrier to file in the EPO is shockingly lower than for the PGR
process. The philosophy behind this low barrier to entry at the
EPO has always been that opposition is a sort of quality check.1'
The EPO "welcomes" the participation of other parties to ensure
that only valid patents are granted.' 9 The USPTO's concern with
recovering the costs of operation appears to outweigh any
"welcoming" considerations.'

10 SUPPLEMENT TO OFFICIAL JOURNAL OF THE EUROPEAN PATENT OFFICE,

Schedule of Fees and Expenses Applicable as from I April 2012, at 17 (Mar.
2012), availableat http://archive.epo.org/epo/pubs/oj012/03_12/03_supl2.pdf.
1o5 See Case G 3/99,
Admissibility of Joint Opposition or Joint
Appeal/HOWARD FLOREY, 2002 O.J.E.P.O. 347, 353 (Enlarged Bd. Appeal,
Feb. 18, 2002), availableat http://archive.epo.org/epo/pubs/oj002/07_02/07 347
2.pdf.
106 Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg.
48,612, 48,672 (Aug. 14, 2012) (to be codified at 37 C.F.R. § 42.15).
107
108

id
DERK VISSER, THE ANNOTATED EUROPEAN PATENT
CONVENTION 226

(19th rev. ed. 2011).
109 Id.
110 The fee set must be "reasonable" in view of the aggregate costs of the
review. 35 U.S.C. §§ 311(a), 321(a) (Supp. V 2011); see also Rules of Practice
for Trials Before the Patent Trial and Appeal Board and Judicial Review of
Patent Trial and Appeal Board Decisions, 77 Fed. Reg. 48612, 48618 (Aug. 14,
2012) ("Therefore, the Office is instead setting fees for these services pursuant
to its authority under 35 U.S.C. 41(d)(2) in this rulemaking, which provides that
fees for all processing, services, or materials relating to patents not specified in
35 U.S.C. 41 are to be set at amounts to recover the estimated average cost to
the Office of such processing, services, or materials.").

112
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A party who is adversely affected can appeal a decision by the
Opposition Division."' If an appeal is filed, the other parties to the
proceedings shall be parties to the appeal proceedings as of right.112
The same is true for PGRs in the United States."13
The Boards of Appeal in Europe have introduced the principle
of the "prohibition of reformatio in peius," which is intended to
prevent the Board from worsening the position of an appealing
party.114 This principle can obviously be applied only in inter
partes proceedings where neither the owner nor the opponent is an
appellant. This can happen when one of the parties has withdrawn
from the proceedings or one of the parties is "only" a party as of
right."'
To institute an appeal, a notice of appeal" 6 must be filed within
two months from the notification of the decision and an appeal fee
needs to be paid within that same time period. "' The notice of
appeal simply needs to identify the appellant, the impugned
decision, and a request defining the subject of the appeal."' Two
months after the deadline for filing the notice, the grounds of
appeal need to be filed."' The statement of grounds of appeal and
the reply of the respondent must contain the party's complete

case.120
"1 European Patent Convention, supra note 25, at art. 107.
112 Id.

"' 35 U.S.C. § 329 (Supp. V 2011).
14 Case G 10/93, Scope of Examination in ex parte Appeal/SIEMENS, 1995
O.J.E.P.O. 172, 172-80 (Enlarged Bd. Appeal, Nov. 30, 1994), available at
http://archive.epo.org/epo/pubs/ojl995/pI71_273.pdf.
"1

Id.

116

European Patent Convention, supra note 25, at art. 108.
Id. The appeal fee is E1,240. SUPPLEMENT TO OFFICIAL JOURNAL

"

OF THE

EPO, EUROPEAN PATENT OFFICE, Schedule of Fees and Expenses Applicable as

from 1 April 2012, 17 (Mar. 2012), available at http://archive.epo.
org/epo/pubs/oj0 12/03_12/03 sup 12.pdf.
118 European Patent Convention, supra note 25, at rule 99(1).
119 Id.

Decision of the Administrative Council of 25 October 2007 Approving
Amendments to the Rules of Procedure of the Boards of Appeal of the European
Patent Office, 2007 O.J.E.P.O. 536, 541, available at http://archive.epo.org/epo/
pubs/oj007/11_07/11_5367.pdf.
120
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D. Estoppel
The concept of estoppel is not established within European
patent law. There is no estoppel generated by opposition
proceedings vis-At-vis later national proceedings. 121 If an opponent
files an opposition that is rejected, that should not preclude the
The
same party from starting national invalidation proceedings.'
opponent can in fact use the same facts, the same evidence, and the
same arguments that he used during the European opposition
procedure in the national procedure.'2 3
In addition, if the opposition is rejected and the requesting
party finds itself in patent litigation in a country where invalidity
arguments may be raised as a defense (e.g., France, England, and
the Netherlands), the party may use the same facts, evidence, and

arguments in the litigation.124
Of course, the fact that the opposition request was rejected may
informally impact how a court views the party's invalidity defense.
However, there are no legal estoppels against the requesting party
who failed in the opposition.'2 5 This stands in stark contrast to
PGRs, which have statutory estoppel provisions.12 6
E. Settlement
The patent owner and the opponent can reach a settlement and
agree that the opponent withdraw his opposition.127 This does not
automatically lead to the end of the opposition. Indeed, the
European Patent Convention allows the Opposition Division to
See generally Glaxo Grp. Ltd. v. Genentech Inc. & Anor, [2008] EWCA
(Civ) 23 (Eng.), [2008] F.S.R. 18 (Eng.).
122 European Patent Convention, supra note 25, at art. 138.
123 There is no legal estoppel. See generally Glaxo Grp.
Ltd., [2008] EWCA
Civ 23 (Eng.), [2008] F.S.R. 18 (Eng.).
121

124

id

See Glaxo Grp. Ltd., [2008] EWCA 23, [2008] F.S.R. 18.
35 U.S.C. § 325(e) (Supp. V 2011).
127 Settlement is not forbidden; two parties might indeed
agree that one party
gets a license for instance and that as a consideration the licensee withdraws his
opposition. This is in contrast to U.S. ex parte reexamination which, once
started, cannot be stopped by settlement between the parties. See discussion
infra Part III.G.
125

126
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examine the facts, evidence, and arguments provided by the parties

"of its own motion."I 28
Although this basic principle is applicable to all procedures
before the European Patent Office, the EPO generally construes the
principle narrowly, reflecting a reluctance to examine "of its own
Rather, opposition
motion" in opposition proceedings. 129
proceedings should resemble national revocation procedures, i.e.
contentious proceedings between two parties with opposing
interests who both should be given equal treatment. 130 This
restrictive view on sua sponte examination is held even stronger
with respect to applying this practice in an appeal procedure of
opposition.131 Indeed, this kind of ex officio examination could be
interpreted as favoring one party or the other.
Parties can settle a PGR, thus setting the PGR apart from U.S.
ex parte reexaminations. 132 In this way, PGRs are similar to
oppositions. In the United States, the parties may agree to settle,
unless PTAB has rendered a decision on the merits.'33 If the PGR
is terminated by settlement, no estoppel attaches to the petitioner.13
This is an important point, and will be discussed further in Part
III.F. Even if a PGR is settled, PTAB nonetheless may have the
discretion to terminate the PGR or proceed to a final written
decision.'
European Patent Convention, supra note 25, at art. 114(1).
Case G 9/91, Power to Examine/ROHM AND HAAS, 1993 O.J.E.P.O.
408, 408-21 (Enlarged Bd. Appeal, Mar. 31, 1993), available at
http://archive.epo.org/epo/pubs/ojl993/p403 475.pdf
0
13 Id. at 412 (emphasizing the fundamental difference between the "classical"
pre-grant opposition and the post-grant opposition that was provided for in the
European Patent Convention).
131 Case G 1/99, Reformatio in Peius/3M, 2001 O.J.E.P.O. 381, 381-400
(Enlarged Bd. Appeal, Apr. 2, 2001), available at http://archive.epo.org/epo/pub
s/oj001/08 09 01/09 3811.pdf.
132 Leahy-Smith America Invents Act, Pub. L. No. 112-29, sec. 6, § 327, 125
Stat. 284, 299 (2011) (codified as amended in scattered sections of 35 U.S.C.).
133 d
128

129

134

d

See 35 U.S.C. § 327 (Supp. V 2011). It remains to be seen what approach
the USPTO will take when it comes to deciding a PGR in which the parties have
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entered a written settlement agreement. See Rules of Practice for Trials Before
the Patent Trial and Appeal Board and Judicial Review of Patent Trial and
Appeal Board Decisions, 77 Fed. Reg. 48,612, 48,648 (Aug. 14, 2012). For
example, Comment 205 of that rulemaking noted that:
One comment recommended that the Board should be required to
terminate the trial upon the filing of a settlement agreement of the parties
and, if necessary, institute a new ex parte proceeding to address any
substantial new question, so that the parties could avoid the potential risk of
an unpatentability decision and estoppel.
Response: 35 U.S.C. 317(a), as amended, and 35 U.S.C. 32 7(a) provide
that if no petitioner remains in the inter partes review or post-grant review,
the Office may terminate the review or proceed to a final written decision.
The rule is consistent with the AIA to provide the Board with the flexibility
to terminate the review or proceed to a final written decision depending on
the particular facts of each proceeding.
Id. Comment 217 further states that:
Several comments suggested that the regulations should require or set a
presumption that the proceeding would be terminated by the Board if all
petitioners in a proceeding have settled.
Response: The comments have not been adopted because 35 U.S.C.
317(a), as amended, and 35 U.S.C. 327(a) provide that if no petitioner
remains in the review as a result of a settlement, the Office may terminate
or proceed to rendering final written decision. Further, 35 U.S.C. 135(e)
and (f), as amended, provide some discretion to continue aspects of a
proceeding. The statutory language for inter partes and post-grant review
confers discretion to the Office in determining based on the facts in a
particular review whether to terminate or proceed to final written decision.
In certain circumstances, conditioning termination on the filing of a related
paper may be appropriate. For example, where the patent owner has agreed
that the claims in dispute are unpatentable, termination appropriately may
be conditioned on the submission of a disclaimer of the claims in dispute.
Id. at 48,649. Likewise, Comment 218 notes:
One comment suggested that the patentability of a patent should not be
subject to settlement.
Response: As provided in 35 U.S.C. 317(a), as amended, and 35 U.S.C.
327(a), if no petitioner remains in the review as a result of a settlement, the
Office may terminate or proceed to rendering final written decision. The
statutory language confers discretion to the Office in determining based on
the facts in a particular review whether to terminate or proceed to final
written decision. Therefore, patentability is not subject to settlement.
Moreover, the termination of a review because of a settlement has no
statutory estoppel effect. See 35 U.S.C. 317(a), as amended, and 35 U.S.C.
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F. Relation to Litigation and OtherProceedings
The opposition proceeding does not automatically take
precedence over corresponding national invalidity proceedings.136
In addition, if there is related patent infringement litigation, the
national court may or may not stay the litigation while the
opposition is resolved; different countries' courts have different
conventions. 3 1
III. AIA PGRs
The AIA became law on September 16, 2011, significantly
altering the Patent Act of 1952.'3 Under the AIA, the inter partes
reexamination was changed into a new post-grant review or a new
IPR while ex parte reexamination remains unaltered. 13 PGR
allows a third party, not the owner of the patent, to file a petition to
institute a post-grant review, effectively requesting that the patent

327(a). Similarly, 35 U.S.C. 135(e) and (f), as amended, specifically
provide discretion to consider patentability after an agreement.
Id.
136 See generally, e.g., Glaxo Grp. Ltd. v Genentech Inc. & Anor, [2008]
EWCA Civ 23 (Eng.), [2008] F.S.R. 18 (Eng.).
m37
See Michael C. Elmer & Stacy Lewis, Where to Win: Patent-Friendly
Courts Revealed, MANAGING INTELL. PROP., September 2010, available at
http://www.finnegan.com/files/upload/Articles%20and%20other/ 20Resources%
20-%20PDF%2OFiles/Managing IntellectualPropertyWhereto winpatent
friendly courts revealed_09 10.pdf. Each case will be decided on its particular
facts, of course, but countries like England, France, and Germany will typically
not stay litigation pending the outcome in an opposition. Id. Validity and
infringement may both be at issue in litigation in England and France, and the
courts will judge the validity issue based on national standards. Id. Germany is
a bifurcated system where the courts only determine infringement, but the
German courts will typically proceed with the litigation. Id. Courts in both
England and Germany are relatively fast (twelve to eighteen months from filing
to a decision), and will not typically delay a proceeding by staying the action
pending the outcome of an opposition. Id. In contrast, courts in Italy, where
proceedings are usually slower, may be likely to stay litigation pending the
outcome of an opposition because that may narrow the issues that eventually are
tried. Id.
138 See Leahy-Smith America Invents Act secs. 1-37.
"9 Id. sec. 6.
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claims be canceled.'4 0 PGR can be sought on 35 U.S.C. §§ 102 or
103 grounds.141 Additionally, PGR can be based, inter alia, on 35
U.S.C. §§ 101 and 112 grounds, with the exception of the best
mode requirement.' 42 By comparison, IPR is restricted to issues
under 35 U.S.C. §§ 102 and 103.143
Furthermore, the standard of review is that a request for PGR
will be granted if the Director believes that "it is more likely than
not that at least 1 of the claims challenged in the petition is
unpatentable" or the petition raises a "novel or unsettled legal
question that is important to other patents or patent applications."l4 4
A. Effective Dates
Sections 321-329 of Title 35 of the U.S. Code contain the new
statutory provisions relating to PGR.'45 These provisions became
effective September 16, 2012.146 However, except with respect to
the new transitional program for CBM patents and pending
interferences,'47 they will apply only to a U.S. patent containing at
140 d.
1' See 35 U.S.C. § 324(a) (Supp. V 2011); see also 35 U.S.C. §§ 102-103
(2006 & Supp. V 2011).
42
1 See 35 U.S.C. §§ 101, 112 (2006 & Supp. V 2011).
143 See id. §§ 102-103.
'44 Leahy-Smith America Invents Act, Pub. L. No. 112-29, sec. 6, 125 Stat.
284, 306-07 (2011) (codified as amended in scattered sections 35 U.S.C.,
including 35 USC § 324 (Supp. V 2011)).
145
146

Id.
d

For interferences pending on September 16, 2012, the Director of the PTO
shall either let them proceed under the old law or be dismissed without prejudice
to the filing of a PGR. See id.; see also Rules of Practice for Trials Before the
Patent Trial and Appeal Board and Judicial Review of Patent Trial and Appeal
Board Decisions, 77 Fed. Reg. 48,612, 48,677 (Aug. 14, 2012) (to be codified at
37 C.F.R. § 90.1). A final rulemaking from the PTO states that:
To the extent that an interference proceeding under 35 U.S.C. 135 is
available and judicial review of that decision is available, the Office will
continue to apply the regulations as they existed when the AIA was enacted
(or as subsequently modified prior to July 1, 2012) to those proceedings.
Lastly, note that certain interferences may be deemed to be eligible for
judicial review as though they were derivation proceedings.
147
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least one claim with an effective filing date on or after March 16,
2013.14' This is important for practitioners who are planning patent
strategy because it means the PGR tool in general is not available
for at least another year. For now, therefore, there is not even a
question of using a PGR in tandem with a European opposition.
For non-business method patents and for patents not in pending
interferences, it is unlikely that the first PGR petitions will be filed
before 2014, as it will be necessary to wait for patents to issue
from applications containing at least one claim with an effective
filing date after March 15, 2013.149
B. Parties

Under the new PGR proceeding, all real parties-in-interest
must be identified in the petition requesting PGR.'so This marks a
major difference with EPO oppositions and signals a dramatic
change in the United States from ex parte reexamination.
Designing PGR as an inter partes procedure requires the
identification of the real party in interest and reflects Congress'
Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg. at
48,625.
148 Leahy-Smith America Invents Act, sec. 6(f)(2)(A)
("The amendments
made by subsection (d) shall take effect upon the expiration of the 1-year period
beginning on the date of the enactment of this Act and, except as provided in
section 18 and in paragraph (3), shall apply only to patents described in section

3(n)(1).").
149 It is

very likely that the first PGRs that do not relate to business method
patents or interferences will be filed even later than 2014. While there is
variation depending on the technology examining group, currently the average
pendency from filing to issue in the USPTO is 33.7 months. USPTO Annual
Reports, Table 4: Patent Pendency Statistics (FY 2011), U.S. PATENT AND
TRADEMARK OFFICE, http://www.uspto.gov/about/stratplan/ar/2011/oai_05_wlt
04.html (last visited Nov. 15, 2012).
s0 37 U.S.C. § 322(a)(2) (Supp. V 2011); Rules of Practice for Trials Before
the Patent Trial and Appeal Board and Judicial Review of Patent Trial and
Appeal Board Decisions, 77 Fed. Reg. at 48,677 (to be codified at 37 C.F.R.
§ 42.80); Changes to Implement Inter Partes Review Proceedings, Post-Grant
Review Proceedings, and Transitional Program for Covered Business Method
Patents, 77 Fed. Reg. 48,680, 48,682, 48,729 (Aug. 14, 2012) (to be codified at
37 C.F.R. § 42.201).
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objective to make the new cancellation proceedings quasijudicial.'5 '
What is similar between PGR and EPO oppositions is that the
proceeding is filed by a third party, not the patent owner. For
patent owners wishing to request reexamination of their own
patents in the United States, ex parte reexamination remains
available. Ex parte reexaminations can be filed with the USPTO
without disclosing the real party in interest.'52 The challenger can
be effectively anonymous. This was not changed by AIA, and is
similar to an EPO opposition in that a law firm or "straw man" is
often used to shield the identity of the real party in interest.'53
If there are multiple PGR requests for the same patent, the
USPTO Director has discretion to consolidate the actions into one
PGR proceeding.'5 4 The consolidation may be requested by either
the petitioner or the patent owner."' According to the USPTO
rules, however, the request must be filed within one month of the
institution of the PGR. 156 In addition to being authorized to
consolidate multiple PGR requests, the USPTO Director is also
authorized to stay, transfer, consolidate, or terminate any other

's' 157 CONG. REC. S1375-76 (daily ed. Mar. 8, 2011). "Quasi-judicial" is
used to indicate an administrative proceeding that has incorporated some aspects
of traditional litigation, such as, inter alia, some discovery, the possibility of an
oral hearing, and estoppel. Id.
152 35 U.S.C. § 302 (2006).
1' 35 U.S.C. § 322(a)(2) (Supp. V 2011). A "straw man" is often used in the
U.S. to request ex parte reexamination when anonymity is desired. Id. In
contrast, under AIA, a petition for PGR must be filed by a real party in interest.
See discussion infra Part III.B.
154 35 U.S.C. § 325(c) (Supp. V 2011).
'ss Id.; Changes to Implement Inter Partes Review Proceedings, Post-Grant
Review Proceedings, and Transitional Program for Covered Business Method
Patents, 77 Fed. Reg. at 48,731 (to be codified at 37 C.F.R. § 42.222(b)).
156 Changes to Implement Inter Partes Review Proceedings, Post-Grant
Review Proceedings, and Transitional Program for Covered Business Method
Patents, 77 Fed. Reg. at 48,692, 48,731 (to be codified at 37 C.F.R.
§ 42.222(b)).
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USPTO proceeding involving the patent in PGR.'" This includes
the PGR itself.'
C. Grounds and Threshold
A request for PGR will not be granted unless the USPTO
Director determines that the information presented in the petition,
if not rebutted, would demonstrate that it is "more likely than not
that at least one of the claims challenged in the petition is
unpatentable," or the petition raises a novel or unsettled legal
question that is important to other patents or patent applications.'5 9

. 35 U.S.C. § 325(d) (Supp. V 2011).
1 Id.
159 Id. § 324(a)-(b); Changes to Implement Inter Partes Review Proceedings,
Post-Grant Review Proceedings, and Transitional Program for Covered Business
Method Patents, 77 Fed. Reg. at 48,685, 48,730 (to be codified at 37 C.F.R.
§ 41.208(c)). Contrary to what might seem the natural presumption-that "more
likely than not" means a greater than fifty percent chance that at least one of the
claims challenged is unpatentable and that "more likely than not" rather than
"by a preponderance of evidence" is used in this statutory section because the
arguments made by the challenger will be considered by themselves, apart from
any argument the patentee might make-the USPTO has indicated that the
patentee's response, if any, will be considered. See id. Once PGR is instituted,
the challenger bears the burden of proving a position of unpatentability by a
preponderance of evidence. Id. at 48,686. Presumably, the challenger's
evidence and arguments will be considered in view of .the patentee's evidence
and arguments to adjudicate if the challenger has "more likely than not" carried
its burden on the position. Additionally, it seems that for those PGRs to which
the first-inventor-to-file provisions of AIA apply, there will, in the early years,
be numerous instances of "a novel or unsettled legal question that is important to
other patents or patent applications." Id. at 48,685; see Leahy-Smith America
Invents Act, Pub. L. No. 112-29, sec. 6, 125 Stat. 284, 285 (2011) (codified as
amended in scattered sections of 35 U.S.C.). Such legal questions appear to
constitute a basis for PGR, at least in the immediate future, even if the "more
likely than not" standard is not satisfied. Somewhat surprisingly, the USPTO
indicated that this ground will be used "sparingly." See Changes to Implement
Inter Partes Review Proceedings, Post-Grant Review Proceedings, and
Transitional Program for Covered Business Method Patents, 77 Fed. Reg. at
48,692. It is also surprising that the USPTO indicated that the "reasonable
likelihood" standard for an IPR, said to mirror the preliminary injunction
standard, is actually a lower standard than PGRs "more likely than not." See id.
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In the United States, a claim may be unpatentable for a number of
reasons, including prior art anticipation or obviousness, lack of
utility, failure to recite patent eligible subject matter, and failure to
meet the requirements of 35 U.S.C. § 112 (definiteness, written
description, and enablement).' 60 In PGR, any of those issues may
be raised.16 '
In this aspect, PGR is somewhat similar to an EPO opposition,
which can also be filed on a range of issues beyond just prior art
patents and printed publications.162 One might conclude from the
statutory context that the broader grounds of PGR incentivize
earlier challenge of patents, which could allow potential flaws to
be addressed sooner. Once the nine-month PGR window closes,
however, third party challengers are restricted to IPR or ex parte
reexamination, with narrower grounds available for challenging
patentability of the claims."

The PGR standard is higher than the standard of "substantial
new question of patentability" that has, for example, applied, and
still applies to ex parte reexamination proceedings. 164 The
legislative history of the AlA indicates that the PGR threshold of
"more likely than not" was explicitly intended to be higher than the
"substantial new question of patentability" threshold for ex parte
The Congressional Record indicates the
reexamination. 165
following:
Specifically, to initiate a post issuance review under the new post grant
or transitional proceedings, it is not enough that the request shows a
at 48,702; see also 157 CONG. REC. S 1375 (daily ed. Mar. 8, 2011) (statement of
Sen. Jon Kyl).
160 It can be argued that double-patenting, a judicially-created ground of
invalidity, could also be raised in a PGR petition.
161 35 U.S.C. § 32 1(b) (Supp. V 2011).
162 European patent law does not make a distinction between prior art that is
printed or not. European Patent Convention, supra note 25, at art. 54(2) ("The
state of the art shall be held to comprise everything made available to the public
by means of a written or oral description, by use, or in any other way, before the
date of filing of the European patent application.").
163 35 U.S.C. §§ 302, 311(b) (2006 & Supp. V 2011).
1
37 C.F.R. § 1.510 (2012).
165 35 U.S.C. § 303(a) (2006 & Supp. V 2011).
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substantial new question of patentability but must establish that "it is
more likely than not that at least 1 of the claims challenged in the
petition is unpatentable." The heightened requirement established by
this bill means that these proceedings are even better shielded from
abuse than the reexamination proceedings have been. In fact, the new
higher standard for post issuance review was created to make it even
more difficult for these procedures to be used as tools for
harassment. 166

Comments in the legislative history also suggest that the "more
likely than not" of PGR is a higher threshold than the "reasonable
likelihood of success" threshold for the other new U.S.
cancellation proceeding, IPR. 167 The reason given is that the
broader grounds for PGR may require discovery to be properly
addressed. 168
Of course, legislative history, dismissively labeled by Justice
Scalia as a "fool's errand,"l 69 did not carry the day before the
Federal Circuit in litigation to determine whether a Patent Term
Extension could exceed five years from the patent's issuance.o
166 157 CONG. REC. S5428 (daily ed. Sept. 8, 2011) (statement of Sen. Patrick
Leahy); see also 157 CONG. REC. S 1363 (daily ed. Mar. 8, 2011) (statement of
Sen. Patrick Leahy) ("The proceeding has a higher threshold than current
reexamination before the PTO will even undertake a review of the patent."); 157
CONG. REC. S 1375 (daily ed. Mar. 8, 2011) (statement of Sen. Jon Kyl).
167 Changes to Implement Inter Partes Review Proceedings, Post-Grant
Review Proceedings, and Transitional Program for Covered Business Method
Patents, 77 Fed. Reg. 48,680, 48,702 (Aug. 14, 2012) (to be codified at 37
C.F.R. pt. 42).
168 157 CONG. REC. S1375 (daily ed. Mar. 8, 2011) (statement of Sen. Jon
Kyl). The USPTO indicated that the "reasonable likelihood" standard for an
IPR, said in the legislative history to mirror the preliminary injunction standard,
is actually a lower standard than PGR's "more likely than not." See id.
169 Robert Barnes, Divining Congress'sIntent, WASH. POsT, Apr. 23, 2012, at
Al l, available at http://www.washingtonpost.com/politics/divining-congresssintent/2012/04/22/gIQAhBPhaT_story.html ("What does Congress want? ...
[O]ne piece of evidence is always controversial . . .. The evidence is the
legislative history of an act . . .. [Justice] Scalia says that 'examining the entrails

of legislative history' is a fool's errand.").
1o See Hoechst v. Quigg, 917 F.2d 522 (Fed. Cir. 1990); see also Caraco
Pharm. Labs., Ltd., v. Novo Nordisk A/S, 132 S. Ct. 1670, 1687 (2012)
(focusing on statutory context rather than legislative history to determine the
scope of the counterclaim provision in the Hatch Waxman Act, since the statute
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Eventually, PGR decisions and U.S. case law will provide
practitioners with a better understanding of what will be sufficient
in a petition to satisfy the various threshold standards of ex parte
reexamination, PGR, and IPR, and how they differ from each
other.
By statute, whether the PGR petition meets the threshold is
apparently judged only on the petition (not the petition and the
patent owner's response)."' However, the USPTO rules governing
PGR indicate that an assessment of whether the PGR threshold is
met will consider the patent owner's preliminary response. 172
Other grounds for rejecting the petition are failure to comply with
the petition requirements or because the Director is authorized
under the AIA to restrict the number of PGR requests granted in
the first four years the new procedure is in effect."'
D. Procedureand Timing
A petition requesting PGR must be 4 filed "not later than ...
[nine] months after the date of the grant of the patent or of the
issuance of a reissue patent.""' This is, of course, the same time
frame as an EPO opposition and marks PGR as a descendant of
EPO oppositions."' Nine months after issuance is not a very long
time, so competitors are forced to respond quickly. Failure to file a
PGR request within nine months of issuance leaves a third party
itself is "where the best proof of what Congress means to address almost always
resides").
"' 35 U.S.C. § 324 (Supp. V 2011).
172 Changes to Implement Inter Partes Review Proceedings, Post-Grant
Review Proceedings, and Transitional Program for Covered Business Method
Patents, 77 Fed. Reg. 48,680, 48,730 (Aug. 14, 2012) (to be codified at 37
C.F.R. pt. 42).
1
Leahy-Smith America Invents Act, Pub. L. No. 112-29, sec. 6(f)(2)(b), 125
Stat. 284, 299 (2011) (codified as amended in scattered sections of 35 U.S.C.);
see also Changes to Implement Inter Partes Review Proceedings, Post-Grant
Review Proceedings, and Transitional Program for Covered Business Method
Patents, 77 Fed. Reg. at 48,729 (demonstrating the regulation drafted as a result
of the AIA section cited above).
174 35 U.S.C. § 324(c).
7
' s Id. § 321(c).
176 See supra Part
II.C.
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with only narrower grounds for challenge through the options of ex
parte reexamination or IPR."'
Once a petition is received, the patent owner has three months
to file a preliminary response."' A decision as to whether or not to
grant the petition for PGR must then be made within three months
of receiving the preliminary response."9 The statute requires that
"the final determination in any [PGR] be issued not later than [one]
year after the date on which the Director notices the institution of a
proceeding," with the possibility of an extension of six months.'
These very aggressive deadlines highlight a major difference with
EPO oppositions, which do not have a statutory time limit. No
time limits, along with allowing for any alleged infringer to
intervene in opposition proceedings after the nine-month
timeframe has expired, mean that EPO oppositions can run several
months or even years.
Accordingly, PGR will be conducted exclusively by the PTAB,
which came into being on September 16, 2012.m' That exclusive
jurisdiction before the PTAIB in the first instance stands in stark
contrast to ex parte reexamination, the long-standing U.S.
administrative validity challenge proceeding that was substantively
not changed in the AIA.18 2 However, ex parte reexamination will
' In the United States, requests for exparte reexaminations and the new inter
partes review are restricted to prior art based on patents and printed
publications. See 35 U.S.C. § 302 (2006); 35 U.S.C. 3 11(b) (2006 & Supp. V
2011).
"8 35 U.S.C. § 323 (Supp. V 2011); Changes to Implement Inter Partes
Review Proceedings, Post-Grant Review Proceedings, and Transitional Program
for Covered Business Method Patents, 77 Fed. Reg. at 48,730.
"9 35 U.S.C. § 324(c)(1) (Supp. V 2011). The decision to grant or deny a
petition for PGR is not appealable. Id. § 324(e).
"s0 d. § 326(a)(l 1). The USPTO noted that such extensions of the one-year
period are anticipated to be rare. Changes to Implement Inter Partes Review
Proceedings, Post-Grant Review Proceedings, and Transitional Program for
Covered Business Method Patents, 77 Fed. Reg. at 48,695. Note that the parties
cannot request an extension, only the Director "for good cause shown." 35
U.S.C.A. § 326(a)(l 1). The Director may adjust the time periods in the case of
joinder. 35 U.S.C.A. § 325(c) (West Supp. 2012).
"s 35 U.S.C. § 326(c).
182 See 35 U.S.C. § 302. (2006).
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continue to be heard in the first instance by examiners in the CRU
of the USPTO.'
Before the PTAB, both the patentee and the petitioner have a
"right to an oral hearing" during the proceeding, 184 and the
petitioner also has "at least one opportunity to file written
comments." '

The challenger's ultimate burden of proof is a

preponderance of the evidence.'8 6
In PGR, the patent owner will have the opportunity to "file
[one] motion to amend the patent" by "cancel[ling] any challenged
... claim" or "propos[ing] a reasonable number of substitute
claims," but, like in an EPO opposition, "the amendment . . . may
not broaden the scope of the . . . claim or introduce new matter."'"8

Although the AIA indicates the patentee is authorized to make an
amendment, the USPTO Rules include a condition that the
patentee "may file one motion to amend a patent, but only after
conferring with the Board."'"' Further details on the substitute
claims are also provided in the Rules: "The presumption is that
only one substitute claim would be needed to replace each
challenged claim, and it may be rebutted by a demonstration of
need."' 89
An additional motion to amend may be filed only with PTAB
authorization, which may be given "when there is a good cause
showing or a joint request of the petitioner and the patent owner to
materially advance a settlement." 9 0 A motion to amend must be
filed with the patentee's response, unless otherwise indicated by
183 U.S. PATENT

PROCEDURE

&

TRADEMARK OFFICE, MANUAL OF PATENT EXAMINING

§§ 2233, 2236 (2012), available at http://www.uspto.gov/web/offic

es/pac/mpep/mpep-2200.pdf.
184 35 U.S.C. § 326(a)(10).
18
86
'

Id.

§ 326(a)(12).

Id. § 326(e).
187 Id. § 326(d).
188 Changes to Implement Inter Partes Review Proceedings,
Post-Grant
Review Proceedings, and Transitional Program for Covered Business Method
Patents, 77 Fed. Reg. 48,680, 48,730 (Aug. 14, 2012) (to be codified at 37
C.F.R. pt. 42).
id
190 Id. at 48,731; see 35
189

U.S.C. § 326(d)(2).
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PTAB order."' The USPTO specifically indicates that submission
of supplemental information after the response will be a factor in
determining whether to authorize such an additional motion to

amend.19 2
Significantly, either party can appeal a PTAB PGR decision to
the Court of Appeals for the Federal Circuit. " There is no
provision in the AIA to appeal a PTAB decision of PGR to a U.S.
district court.'
Furthermore, the projected twelve- to eighteen-month time
frame for PGR, as well as the addition of more adjudicative
features to the administrative proceeding, is intended to make this
administrative route more efficient and less expensive than district
court litigation. The exact USPTO filing fee for a petition for PGR
has been set at $35,800 for up to twenty claims, and then $800 for
every claim over twenty. "' There is no small or micro entity
discount at this time."' And of course, if the claims of the patent
are sufficiently interrelated, a third party requester will be
incentivized to challenge them all in view of the stiff potential
estoppels against the requester discussed above. Interestingly, the
statute imposes a "reasonable" requirement on the setting of the
fees to be paid by the requester, "considering the aggregate costs of
the post-grant review." 97

191 Changes to Implement Inter Partes Review Proceedings, Post-Grant
Review Proceedings, and Transitional Program for Covered Business Method
Patents, 77 Fed. Reg. at 48,730.
192 Id. at 48,731.
193 35 U.S.C. § 141(c) (Supp. V 2011).
19 id.

Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg.
48,612, 48,672 (Aug. 14, 2012) (to be codified at 37 C.F.R. § 42.15(b)).
196 Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg. at
48,631.
197 35 U.S.C. § 321(a) (Supp
V 2011).
195
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In addition, PGR petitions are limited to eighty pages.' The
USPTO has indicated that there may be further rules "permit[ting]
a refund of a portion of the petition fees in cases where a review is
not instituted."' 9 9 The refunds may promote more participation in
the patent system.
And, of course, the Petitioner will probably hire legal counsel
to prepare the PGR petition. The USPTO estimates that the legal
fee for preparing a PGR is $61,333.200 How close that estimate
comes to reality remains to be seen.
E. Discovery

Discovery in the United States is notoriously time-consuming,
expensive, and expansive, as well as one of the biggest differences
between the U.S. legal system and those of many other countries.20 '
Those working on U.S. patent law reform faced a huge challenge
in reconciling the desire to create an alternative to litigation with a
fundamental belief that an adversarial system leads to the best
result, in this case, strong patents. The quasi-judicial PGR
proceeding provides discovery, much more limited than in U.S.
patent litigation,202 but it is still significantly more extensive than in
EPO oppositions. It appears designed to anticipate typical disputed
issues, control runaway discovery and costs, and maintain a oneyear timeline to finality after the PGR is instituted.
1 Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg. at
48,673 (to be codified at 37 C.F.R. § 42.24(a)(ii)).
'9 Id. at 48,613.
2oo Id. at 48,656.
201 E.g., LAWYERS FOR CIVIL JUSTICE ET AL., LITIGATION COST
SURVEY OF

MAJOR COMPANIES 13, Fig. 9 (2010), availableat http://www.uscourts.gov/usco
urts/RulesAndPolicies/rules/Duke%20Materials/Library/Litigation%2OCost%20
Survey%20of/o20Major%2OCompanies.pdf;
see also John H. Beisner,
Discovery a Better Way: The Need for Effective Civil Litigation Reform, 60
DUKE L.J. 547 (2010); Maurice Rosenberg & Warren R. King, Curbing
Discovery Abuse in Civil Litigation: Enough is Enough, 3 BYU L. REV. 579
(1981).
202 Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg. at
48,673.
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Discovery in PGR is generally "limited to evidence directly
related to factual assertions advanced by either party in the
proceeding." 203 In addition, Congress tried to leapfrog typical
disputes in the initial phases of discovery by making provision for
mandatory initial disclosures. 20 There will be routine discovery of
"exhibit[s] cited in a paper or ... testimony" and "cross
examination of affidavit testimony" without the need to request
authorization from the PTAB.205
The parties also "must serve [all] relevant information that is
inconsistent with a position advanced by the party during the
proceeding concurrent with the filing of the documents or things
that contains the inconsistency." 20 6 Whether that requirement will
create a discovery monster, particularly for patentees, remains to
be seen.
For any additional discovery beyond the mandatory disclosures
and the routine discovery, parties will have to agree between
themselves or file a motion for additional discovery. 20 7 Additional
discovery in PGR is explicitly limited to "evidence directly related
to factual assertions advanced by either party in the proceeding" 208
and will only be granted upon a showing of "good cause." 209
According to the commentary accompanying the USPTO Rules, to
35 U.S.C. § 326(a)(5) (Supp V 2011); Changes to Implement Inter Partes
Review Proceedings, Post-Grant Review Proceedings, and Transitional Program
for Covered Business Method Patents, 77 Fed. Reg. 48,680, 48,731 (Aug. 14,
2012) (to be codified at 37 C.F.R. pt. 42).
204 Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg. at
48,673.
203

205 Id.
206

Id ("This requirement does not make discoverable anything otherwise
protected by legally recognized privileges such as attorney client or attorney
work product. This requirement extends to inventors, corporate officers, and
involved in the preparation or filing of the documents or things.").
persons
20 7
,d
20 8
1d
209 Changes to Implement Inter Partes Review Proceedings,
Post-Grant
Method
Business
for
Covered
Program
Review Proceedings, and Transitional
Patents, 77 Fed. Reg. 48,680, 48,731 (Aug. 14, 2012) (to be codified at 37
C.F.R. pt. 42).
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show good cause, a party would be required to make a particular
and specific demonstration of fact, and the standard is lower than
the "interests of justice" applied in additional discovery motions in
IPR.2 10
What discovery motions exactly will or will not be granted will
likely be very case-specific, and even the general tendencies of the
PTAB will not be clear until the first PGR proceedings become
publicly available. As of right now, it is unclear how much
additional discovery can occur in a PGR proceeding. Overall,
however, discovery in PGR should foresee typical disputed issues,
restrict runaway discovery, and assist PTAB in sustaining the oneyear time frame. It should be significantly less than what is
required in U.S. patent litigation, 211 but will likely still be
significantly more burdensome than any disclosure required in an
EPO opposition.
F. Estoppel
The inclusion of significant estoppel consequences in PGR
marks another significant difference from EPO oppositions. 212
EPO oppositions do not include the restriction that a challenger
must forfeit arguments for any future proceedings.2 13 However, if a
PGR results in a final written decision by PTAB, the PGR
petitioner is estopped from raising "any ground that the petitioner
Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg. at
48,622,48,641.
211 Id. at 48,621, 48,632 ("Unlike in proceedings under the Federal Rules of
Civil Procedure, the burden of justifying discovery in Board proceedings would
lie with the party seeking discovery. Proceedings before the Board differ from
most civil litigation in that the proponent of an argument before the Board
generally has access to relevant evidence that is comparable to its opponent's
access. Consequently, the expense and complications associated with much of
210

discovery can be avoided .

...

The rules provide for an efficient and controlled

procedure to secure the just, speedy, and inexpensive resolution of every
proceeding coming before the Board. § 42.1(a).").
212 See discussion supra Part
II.D.
213 There is no legal estoppel between a European opposition
and a national
patent litigation in a European country. See generally Glaxo Grp. Ltd. v
Genentech Inc. & Anor, [2008] EWCA Civ 23 (Eng.), [2008] F.S.R. 18 (Eng.).
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raised or reasonably could have raised during that post-grant
review" in any future USPTO, district court, or U.S. International
Trade Commission proceeding.214
These estoppel consequences suggest that the petitioner needs
to disclose all potential invalidity claims, as they will be
unavailable in later litigation.
PGR estoppels, however,
presumably cannot apply to infringement defenses in subsequent
litigation because no infringement issues are raised in a PGR. As
noted above, PGR is limited to "any ground . . . relating to

invalidity of the patent or any claim."2 15 Therefore, all invalidity
claims asserted will be raised and resolved during a PGR
proceeding. Furthermore, a petitioner that initiates PGR needs to
note that apparently all invalidity defenses will be determined in
PGR.26
In a subsequent infringement action, assuming that the
petitioner loses on all validity grounds, defenses left would appear
to include inequitable conduct and non-infringement. In particular,
estoppel will apply to all validity grounds raised or that could have
reasonably been raised.2 17
The estoppel provision must also be understood in the context
of requirements imposed upon the petitioner to "identify] . . . each
214 35 U.S.C. § 325(e)(1)-(2) (Supp. V 2011); Rules of Practice for Trials
Before the Patent Trial and Appeal and Judicial Review of Patent Trial and
Appeal Board Decisions, 77 Fed. Reg. at 48,676.
2

35 U.S.C. § 321(b) (Supp. V 2011).
Id

("A petitioner in a post-grant review may request to cancel as
unpatentable one or more claims of a patent on any ground that could be raised
under paragraph (2) or (3) of section 282(b) (relating to invalidity of the patent
or any claim)."). Additionally, 35 U.S.C. § 282(b)(2)-(3) reads:
(2) Invalidity of the patent or any claim in suit on any ground specified in
part II as a condition for patentability [§§ 102 and 103].
(3) Invalidity of the patent or any claim in suit for failure to comply with(A) any requirement of section 112, except that the failure to disclose the
best mode shall not be a basis on which any claim of a patent may be
canceled or held invalid or otherwise unenforceable; or
(B) any requirement of section 251 [reissue].
35 U.S.C. § 282(b)(2) (2006 & Supp. V 2011).
217 35 U.S.C. § 322(e) (Supp. V 2011).
216
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claim challenged," the grounds for each challenge, and the
evidence supporting each challenge. 218 In other words, the
petitioner will want to carefully consider challenging all
appropriate claims and consider assembling and presenting up
front compelling evidence to set forth and support any and all
grounds for challenging any appropriate claim.
Until now, this Article has discussed estoppel running against
the petitioner. But note 37 C.F.R. § 42.73(d)(3), which explains
the estoppel that applies to the patentee:
A patent applicant or owner is precluded from taking action
inconsistent with the adverse judgment, including obtaining in any
patent: (i) A claim that is not patentably distinct from a finally refused
or cancelled claim; or (ii) An amendment of a specification or of a
drawing that was denied during the trial proceeding, but this provision
does not apply to an application or patent that has a different written
description.21 9

The estoppel provisions, moreover, only run one way (from PGR
to litigation). No mention is made in the AIA indicating that
estoppel applies in PGR to issues raised by (or that could
reasonably have been raised by) the petitioner in litigation. This
"one way" estoppel may turn out to be very significant.
Of course, if a petitioner were in litigation, the nine-month
post-issuance window is likely closed. At that point, the third
party might still be at liberty to explore other administrative
options such as exparte reexamination and IPR.
If timing allows, such options and the limited "one way"
estoppel are interesting in light of the recent Federal Circuit
decision in In re Baxter International,Inc.220 In Baxter, Fresenius
filed a declaratory judgment action in federal district court
218

Id. § 322(a)(3).
Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg. at
48,676 (to be codified at 37 C.F.R. § 42.73(d)(3)). The USPTO clarified that
estoppel does not apply against a claim that could have been filed in response to
any properly raised ground of unpatentability for a finally refused or cancelled
claim. Id. at 48,649.
220 678 F.3d 1357 (Fed. Cir. 2012), reh'g denied en banc, 698 F.3d 1349 (Fed.
Cir.).
219
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requesting that Baxter's patent claims to a hemodialysis machine
be declared invalid. 2 2' Fresenius lost, failing to prove invalidity by
clear and convincing evidence, in the face of the presumption of
validity enjoyed by the patent.222
But, while the litigation was ongoing, Fresenius filed a
reexamination request, again targeting Baxter's patent. 223 In the
reexamination, without the presumption of validity and under the
lower evidentiary standard of preponderance of the evidence
(rather than clear and convincing evidence), and in view of the
broadest reasonable claim construction standard applied during a
reexamination proceeding, Fresenius succeeded through ex parte
reexamination in obtaining cancellation of the same claims that
were upheld in litigation.224
According to the Baxter panel, Fresenius properly filed the
request for reexamination "during the period of enforceability of
[the] patent," 225 and he was entitled to do so: "Congress has
provided for a reexamination system that permits challenges to
patents by third parties, even those who have lost in prior judicial
proceedings."2 26 Ultimately, the two proceedings applied different
burdens of proof, with different presumptions of validity under
different claim construction standards, relied on different records,
and arrived at different conclusions.22 7
The Federal Circuit panel in Baxter expressed the hope that the
court and USPTO would come to the same conclusion when faced
with the same evidence and arguments.228 But because of the
different presumptions and standards of proof, an alleged infringer
Id. at 1359-60.
Id. at 1360.
223 Id. at 1359-60.
224 Id. at 1360-61, 1364-65.
225 37 C.F.R. § 1.510
(2012).
226
Baxter, 678 F.3d at 1365.
227 Id. at 1364-65
("More fundamentally, the PTO in reexamination
proceedings and the court system in patent infringement actions 'take different
approaches in determining validity and on the same evidence could quite
correctly come to different conclusions." (quoting In re Swanson, 540 F.3d
1368, 1377 (Fed. Cir. 2008))).
221

222

228 Id.
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could, just as Fresenius did in Baxter, lose in litigation but find
solace through a USPTO ex parte reexamination cancelling all
claims of concern to the alleged infringer. 2 29
Thus, assuming proper timing, the alleged infringer unsatisfied
with his court proceedings can properly bring a post-grant
proceeding in the USPTO. There is no estoppel preventing such an
action.
G. Settlement
The new section 327 authorizes termination of PGR if the
parties settle.230 Even if there is a settlement, the PTAB "may
independently determine any question of jurisdiction, patentability,
or Office practice." 231' The AIA makes clear that even if no
petitioner remains in PGR, the USPTO may nonetheless proceed to
a final written decision.2 32
Id. Similarly, in patent litigation between Research in Motion and NTP,
Research in Motion agreed to pay $612 million in settlement, but then managed
to have all claims of the patents at issue cancelled when ex parte reexaminations
concluded post-settlement. See NTP, Inc. v. Research in Motion, Ltd., 418 F.3d
1282 (Fed. Cir. 2005); Press Release, Research in Motion, Research In Motion
and NTP Sign Definitive Settlement Agreement to End Litigation (Mar. 3,
2006), http://press.rim.com/newsroom/press/2006/pressrelease-981.html.
230 35 U.S.C. § 327 (Supp. V 2011).
231 Rules of Practice for Trials Before the Patent Trial and Appeal
Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg.
48,612, 48,625, 48,677 (Aug. 14, 2012) (to be codified at 37 C.F.R. pt. 42); see
also 35 U.S.C.A. § 327(a).
232 Rules of Practice for Trials Before the Patent Trial and Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg.. at
48,625, 48,648 ("The rule is consistent with 35 U.S.C. 135(e), as amended,
where the Board is not required to follow the settlement agreement if it is
inconsistent with the evidence. The rule is also consistent with 35 U.S.C. 317,
as amended, and 35 U.S.C. 327, which provide that the Board may proceed to a
229

final written decision even if no petitioner remains in the proceeding . .

..

35

U.S.C. 317(a), as amended, and 35 U.S.C. 327(a) provide that if no petitioner
remains in the inter partes review or post-grant review, the Office may
terminate the review or proceed to a final written decision. The rule is
consistent with the AIA to provide the Board with the flexibility to terminate the
review or proceed to a final written decision depending on the particular facts of
each proceeding.").
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How likely is it that the USPTO would provide a written
decision notwithstanding settlement? The USPTO addressed this,
pointing out that it could provide such a written decision if the
record clearly shows that the claims are unpatentable and the
patent owner has not filed a response or an amendment.23 3
Providing for settlement by the parties, and providing for
termination even if the parties have settled, represents a similarity
with EPO oppositions.23 4 The opportunity to settle is a huge
change from ex parte reexamination in the USPTO, which is a oneway street: Once it begins, reexamination is the horse that has
bolted out of the barn and cannot be stopped.
Estoppel attaches only to a PGR that results in a final written
decision.235 If PGR is terminated by settlement prior to a written
PTAB decision on the merits, no estoppel attaches to the
petitioner.2 36
H. Relation to Litigation and Other Proceedings
The relationship between PGR and other litigation or
proceedings further distinguishes PGR from an EPO opposition.
Under AIA, there is no PGR available if, prior to filing a petition
for PGR, the petitioner filed a civil action challenging validity of
the patent (called a "declaratory judgment action" in the United
States).2 37 The AIA also provides that a civil action challenging
validity filed by petitioner on or after the date on which a PGR
petition is filed is "automatically stayed" unless "(A) the patent
owner moves to lift the stay; (B) the patent owner files an action or

233 Id. at 48,648.
234 See supra Part

II.E. Settlement in an opposition is not forbidden; two
parties might indeed agree that one party gets a license for instance and that as a
consideration the licensee withdraws his opposition.
235 3 U.S.C. § 325(e) (Supp. V 2011); Rules of Practice for Trials Before the
Patent Trial and Appeal Board and Judicial Review of Patent Trial and Appeal
Board Decisions, 77 Fed. Reg. at 48,676.
236 35 U.S.C. §§ 317(a), 327(a) (2006 & Supp.
V 2011).
237 35 U.S.C. § 325(a)(1) (Supp. V 2011).
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counterclaim for infringement; or (C) the petitioner moves to
dismiss the civil action."2 38
A counterclaim of invalidity does not qualify as a civil action
challenging validity.239 If a patentee sues for infringement within
three months of patent issuance, "the court may not stay its
consideration of [a] motion for a preliminary injunction . . . on the

basis that a petition for [PGR] has been filed or that such a [PGR]
has been instituted."240 If a PGR is underway, and the patent is
involved in another proceeding or matter before the USPTO, the
Director has discretion to "stay, transfer, consolidate, or terminate
any such matter or proceeding."24 '
IV. STRATEGIC CONSIDERATIONS ACCOMPANYING THE USE OF
EUROPEAN OPPOSITIONS AND POST-GRANT REVIEWS

European oppositions are a time-tested proceeding, and will no
doubt continue to be utilized for the foreseeable future. The AIA
PGR is the new kid on the block. Transitional PGRs for CBM
patents, a cousin of PGR, has existed only for CBM patents since
September 16, 2012.242 The effect of PGR has not been felt
because no patent has yet been issued containing at least one claim
with an effective filing date after March 15, 2013. Hence, no U.S.
patent presently in force qualifies for PGR.
Comments about PGR are necessarily speculative at this point.
The first PGR decisions will have to be analyzed when they issue
Id § 325(a)(2).
Id. § 325(a)(3).
240 Id § 325(b); see also 157 CONG. REC. S1376 (daily ed. Mar. 8, 2011)
(statement of Sen. Jon Kyl) ("This provision strengthens and carries over to
post-grant review the rule of Procter& Gamble Co. v. Kraft Foods Global,Inc.,
549 F.3d 842 (Fed. Cir. 2008).").
241 35 U.S.C. § 325(d); Changes to Implement Inter Partes Review
Proceedings, Post-Grant Review Proceedings, and Transitional Program for
Covered Business Method Patents, 77 Fed. Reg. 48,680, 48,731 (Aug. 14, 2012)
(to be codified at 37 C.F.R. pt. 42).
242 AIA Frequently Asked Questions: Transitional Program for Covered
Business Method Patents, U.S. PATENT AND TRADEMARK OFFICE, http://www.usp
to.gov/aia implementation/faqs covered business methodjsp (last visited Dec. 27,
2012).
238
239
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in order to fully understand the role PGRs will assume in the U.S.
patent system. But speculation certainly can be made.
Congress wanted to provide the patent community with an
alternative to costly, time-consuming, and complicated patent
litigation. PGR provides a new option in the United States that
could be faster and cheaper than traditional U.S. district court
litigation. The grounds for the review are broad, i.e., all validity
issues. That, in combination with the time limit of nine months
after issuance for requesting a PGR, indicates a desire on the part
of Congress that problem patents get resolved before they become
bogged down in litigation.24 3
But the authors have observed an unsettled feeling expressed
informally in the United States that PGR will eviscerate the power
and effect of U.S. patents.24 In other words, the patentee works
very hard to obtain a valid, enforceable, and uninfringed patent.
The patentee is banking on a presumption of validity, a claim
construction hammered out in a Markman hearing, 245 and
protection from a validity attack under the clear and convincing
evidentiary standard, as noted above.246
But then, to the patentee's horror, PGR arises post-issuance.
As discussed above, the court in Baxter noted that in
reexamination, in contrast to civil litigation, there is no
presumption of validity of the claims, and the patentability of the
claims is assessed under a preponderance of the evidence
See also 157 CONG. REC. S5409 (daily ed. Sept. 8, 2011) (statement of
Sen. Charles Schumer); 157 CONG. REC. S5411 (daily ed. Sept. 8, 2011)
(statement of Sen. Orrin Hatch).
244 Although, notably, EPO oppositions have been
around a long time and
have not ruined the European patent system.
245 Markman v. Westview Instruments, Inc. 517 U.S.
370 (1996) (holding that
courts have the exclusive power to interpret patent claims). Markman laid the
foundation for Markman hearings, a pretrial hearing in which judges examine
patent claim evidence. J. Michael Jakes, Using an Expert at a Markman
Hearing: Practical and Tactical Considerations, FINNEGAN (Aug. 2002),
http://www.finnegan.com/resources/articles/articlesdetail.aspx?news-e3962a13b898-4102-8fca-171c656a6ed2.
246 See discussionsupra Part
III.F.
243
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standard. 247 The court further noted that claims are given their
broadest reasonable construction.248 So, the patentee in PGR is
stripped of the presumption of validity, stripped of the clear and
convincing evidentiary shield for invalidity, and is now subject to
Broader claim
the broadest reasonable claim construction.
construction, like a broader strike zone in that peculiar American
institution of baseball, means that more pitches will be strikes. By
analogy, more attacks of unpatentability can be successful than
under the more stringent standards applied in litigation.
It can even be worse if the PGR can be timely filed after the
institution of litigation. Presume the patentee somehow found
itself in a rocket docket of district court litigation or in a very fastmoving International Trade Commission proceeding. And assume
the stars lined up and in such explosively fast proceedings, the
patent challenger was unable to overcome the presumption of
validity by clear and convincing evidence. Hence, in the litigation,
the patent was not proved to be invalid.
Yet, as in Baxter, there should be no estoppels applied against
a PGR requester, who can meet the timing requirements of the
PGR and initiate the PGR.249 And just as in Baxter, the specter
arises that the patentee who won the litigation will have the
relevant claims canceled in the PGR.250 The litigation victory is
thus reduced to a very unsatisfactory pyrrhic victory, and even
apart from a simultaneous or past litigation, the highly valued U.S.
patent can now be thrown into the USPTO in an adversarial
proceeding, with burden of proof, claim construction, and lack of
presumption of validity. All of those facts tilt the PGR toward the
petitioner and against the patentee.
At first glance, however, there may be reluctance to utilize
PGR by a prospective petitioner because of the lack of anonymity
as well as the potential significant estoppel to the petitioner in light
In re Baxter Intern., Inc., 678 F.3d 1357, 1364 (Fed. Cir. 2012), reh 'g
denied en banc, 698 F.3d 1349 (Fed. Cir. 2012).
248 Id. at 1361.
249 See discussion supra Part
III.F.
250 See discussion supra
Part III.F.
247
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of less discovery than could be obtained in patent infringement
litigation. Additionally, there is uncertainty as to how much, if
any, additional discovery beyond the routine discovery will be
obtained in PGR. But that reluctance may well be tempered by the
lower cost, broad statutory grounds of attack, and significant
benefits to the petitioner provided by the U.S. Congress through
the AIA.25 1
As noted above, even the estoppel does not run to every issue
that might benefit the petitioner in PGR.252 It is not seen how
issues, such as of infringement or inequitable conduct, could be
raised.253 Hence, PGR can provide a petitioner with a chance to go
for a knockout blow in the USPTO to cancel claims of concern. At
the same time, issues such as infringement and inequitable conduct
are preserved as defense issues if PGR does not achieve the
petitioner's desired effect. Those are factors that mitigate in favor
of requesting a PGR rather than initiating litigation.
To be sure, PGR was conceived to be in the likeness of
European oppositions. But there are many, many differences
between oppositions and PGRs. In fact, it might be fair to
conclude that they are more different than they are similar. The
outcome in each will have no impact on the other because there is
no res judicata between the tribunals. The different requirements,
rules, procedures, and claims in the patents-at-issue will keep the
two proceedings separate to be used, separately or together, as
facts and circumstances in any particular case unfold.
Certainly the third party who is vigilant and acting quickly
preserves the most options because timing is the key: The ninemonth post-issuance window of both proceedings will rarely, and
only serendipitously, overlap. If the European patent issues first,
See discussionsupra Part III.
See discussionsupra Part III.F.
253 35 U.S.C. § 321(b) is restricted to issues arising
under "paragraph (2) or
(3) of section 282(b) (relating to invalidity of the patent or any claim)." 35
U.S.C. § 321(b) (Supp. V 2011). "Noninfringement, absence of liability for
infringement or unenforceability" is specifically not included and therefore
should not be allowed in PGRs. 35 U.S.C. § 282(b)(1) (2006 & Supp. V 2011).
251

252
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an opposition may be filed within the nine-month window. 254 It is
possible that the proceeding could be finished prior to either the
U.S. patent issuing or the U.S. PGR nine-month window closing.
The European opposition, apparently lacking mountains of expert
and other evidentiary materials, offers an ideal and generally less
expensive opportunity, without any possibility of estoppel, to test
the basic merits of the invalidity case, at least in the context of
European patent claims under European law.
And if the U.S. patent issues first, the proceeding may be over
before the European patent issues (or the nine-month post-issuance
window closes). If the U.S. patent issues first, there is actually a
better likelihood of having the PGR proceeding finished before the
European patent issues (or the nine-month post-issuance window
closes) because of the aggressive statutory timeline of one year
from institution for concluding a PGR proceeding.
Whichever proceeding occurs first, there may be valuable
information gained to use in the second. The requester in the
European opposition, without estoppel effect, may possibly attract
other opponents and harvest prior art in the form of patents and
printed publications that could be used in either U.S. cancellation
proceedings or U.S. litigation.
Hence, who benefits and who is harmed? If the U.S. patent
issues first, PGR is instituted, and the claims of concern are
canceled, the patentee is harmed, certainly in the United States.
But the patentee is probably also harmed in Europe, particularly if
the cancellation was based on the prior art. That prior art can then
be employed by the petitioner and others in Europe in an attempt to
revoke the European patent.
But what if the patentee wins in the United States? In the EPO
opposition, the Opposition Division may be completely unfazed, as
it will apply art, arguments, and evidence under its own European
standards to claims issued by the European Patent Office. And the
U.S and European claims, of course, may substantially differ.

254

See discussion supra Part II.C.
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On the other hand, assume that the European patent issues first,
and an EPO opposition is filed. If the opponent(s) win in Europe,
this may considerably embolden one or more of those opponents to
bring a PGR in the United States. That would particularly be so if
the European opponent(s) achieved revocation based on prior art
and if the claims granted in Europe and the United States are
sufficiently similar. Ultimately, this would harm the U.S. patentee.
In contrast, if the opponent(s) lose in Europe, the appetite to
attack in the United States under PGR may or may not be
diminished. That would depend on the similarity of the U.S.
claims and how any evidence adduced in the European opposition
would play under U.S. standards in the PGR. And of course, as
explained above, the petitioner for PGR in the United States will
take comfort in that issues such as infringement and enforceability
will not be subject to estoppel even if the PGR petitioner is unable
to successfully have the claims canceled by the PTO in the PGR.
In view of that analysis, it is clear that the EPO opposition and
the PGR will not necessarily interfere with each other, nor will one
necessarily preclude the other. In other words, the ships will not
necessarily crash. Rather, all facts and circumstances will be
evaluated as to the merit in the EPO opposition and those in the
PGR. If the chance of revocation is good for both the European
and the U.S. patent claims based on prior art, the petitioneropponent may avail herself of both.
The petitioner-opponent need not worry at all in either the EPO
opposition or the PGR about estoppel on a key issue such as
The Europeans get there by not having any
infringement.
estoppels whatsoever. The Americans get there because, although
there are strict estoppels, no estoppels apparently extend to
infringement defenses, which cannot be raised in PGR, and hence
infringement defenses would be thought to be outside the universe
of issues that reasonably could have been raised in the PGR. If
infringement defenses are not appropriate in a PGR proceeding,
there is no way they could have "reasonably been raised," so there
would not be any estoppel of infringement defenses. Furthermore,
even if revocation cannot be achieved in either proceeding, the
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patentee may well be forced to narrow claims, possibly eliminating
issues of infringement.
The nine-month clock in each proceeding runs independently
because the patents-at-issue in each proceeding are separate. The
EPO opposition nine-month clock starts from the issuance of the
European patent."' The PGR nine-month clock starts from the
issuance of the U.S. patent.256 These issue dates may be close
together or very far apart because the patent prosecutions are
separate and governed by different rules, procedures, and standards
of patentability.
Bringing an EPO opposition will not be precluded on the basis
that a PGR was requested on the related U.S. patent, and vice
versa, no matter what the outcome is of the other proceeding.
Moreover, as noted above, there may be information gained in the
U.S. proceeding because of the possible discovery that could be
used in an EPO opposition, if the EPO opposition is simultaneous
with the PGR, and vice versa.
A possible caveat to the general belief expressed herein that the
two proceedings will not impact each other is that a patentee's
statements in a European opposition, if contradictory to statements
made before the USPTO, could arise in a U.S. litigation context
and even in the PGR as "inconsistent statements."2 57
To be sure, discovery in PGR is more limited than that in
litigation, but the exact contours of PGR discovery remain to be
clearly defined in PGR decisions from PTAB and subsequent
appeals to the Federal Circuit. In what circumstances will a
request for additional discovery meet the "good cause" standard? 258
See discussion supra Part II.C.
See discussion supra Part III.D.
257 See, e.g., Therasense, Inc. v. Becton, Dickinson & Co.,
649 F.3d 1276
(Fed. Cir. 2011) (en banc).
258 Rules of Practice for Trials Before the Patent Trial and
Appeal Board and
Judicial Review of Patent Trial and Appeal Board Decisions, 77 Fed. Reg.
48,612, 48,673 (Aug. 14, 2012) (to be codified at 37 C.F.R. § 42.51(b)(2)(i);
Changes to Implement Inter Partes Review Proceedings, Post-Grait Review
Proceedings, and Transitional Program for Covered Business Method Patents,
255

256
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Practitioners at least know right now there will be automatic, i.e.,
routine, discovery that will extend to all testifying witnesses and
particularly and interestingly, to all inconsistent statements. 259
Also, all that evidence will be presented in the context of an
administrative proceeding (no presumption of validity, broadest
reasonable claim construction, and preponderance of evidence)
rather than civil litigation, which could be at least damaging
enough to a patentee to facilitate a worldwide settlement. In
addition, if the settlement is pursued early enough, any risk is
reduced that either an EPO opposition or a USPTO PGR would
actually terminate on the merits.
But in any event, even some discovery may be useful in both
the PGR and the European opposition. Again, that might tilt the
opponent-petitioner towards filing a PGR in the case where the
U.S. patent of concern issues before the European patent or within
nine months thereof.
For another few months, given the linkage of PGR to claims
with an effective filing date on or after March 16, 2013, a U.S.
patentee, not involved in the new transitional program for CBM
patents and not subject to a pending interference, can slam the door
on any possibility of participating in PGR by doing nothing more
than filing a U.S. application before March 16, 2013.
The authors have heard multiple patentees express a desire to
file patent applications, assuming that their claims will be enabled
and have written description support, before March 16, 2013, to
avoid any possibility of PGR for such patents. But of course, such
patents will, subject to timing issues, and to both IPR and
reexamination post-grant proceedings, so creating a pre-March 16,
2013, filing bubble will not eliminate all post-grant concerns of a
U.S. patentee.

77 Fed. Reg. 48,680, 48,731 (Aug. 14, 2012) (to be codified at 37 C.F.R.
§ 42.224).
25
9 Id. § 42.51(b)(1).
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V. CONCLUSION

Congress intended PGRs to provide a faster, less expensive
alternative to patent litigation, and they probably will fill that role.
Although the EPO opposition was the inspiration for PGR, it is
clear that these two systems will generally remain separate and
pass like ships in the night as PGRs have already and will continue
to become a distinctly American process. Understanding the
similar and disparate features of both PGRs and European
oppositions will be an important task for companies who desire to
have both procedures as part of their fleet.260

Disclaimer:

This Article is public information and has been prepared
solely for educational purposes to contribute to the understanding of U.S.
intellectual property law. These materials reflect only the personal views of the
co-authors and are not individualized legal advice and do not reflect the views of
Finnegan or Cargill. It is understood that each case is fact-specific, and that the
appropriate solution in any case will vary. Therefore, this Article may or may
not be relevant to any particular situation. This Article relates in large part to
Post-Grant Review ("PGR") under the American Invents Act. As of the date of
this Article, although a few PGR proceedings have been requested, it is not
known how the courts will interpret various provisions of PGR. Nor is it known
how Congress might act in the future. Thus, Finnegan, Cargill, and the
individual co-authors cannot be bound either philosophically or as
representatives of their various present and future clients to the comments
expressed in this Article. This Article does not establish any form of attorneyclient relationship with Finnegan, Cargill, or the individual co-authors. While
every attempt was made to insure that these materials are accurate, errors or
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